<SUBMISSION>
<ACCESSION-NUMBER>0001193125-08-096417
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20080430
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20080430
<DATE-OF-FILING-DATE-CHANGE>20080430
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CRYOLIFE INC
<CIK>0000784199
<ASSIGNED-SIC>3841
<IRS-NUMBER>592417093
<STATE-OF-INCORPORATION>FL
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-13165
<FILM-NUMBER>08787926
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1655 ROBERTS BOULEVARD N W
<STREET2>STE 142
<CITY>KENNESAW
<STATE>GA
<ZIP>30144
<PHONE>7704193355
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1655 ROBERTS BOULEVARD N W
<STREET2>STE 142
<CITY>KENNESAW
<STATE>GA
<ZIP>30144
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of Report (Date of earliest event reported): April&nbsp;30, 2008 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>CRYOLIFE, INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Florida</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1-13165</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>59-2417093</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 </B> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive office) (zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (770)&nbsp;419-3355 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Section&nbsp;2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Information </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On
April&nbsp;30, 2008, CryoLife, Inc. (&#147;CryoLife&#148; or the &#147;Company&#148;) issued a press release announcing its financial results for the first quarter ended March&nbsp;31, 2008. CryoLife hereby incorporates by reference herein the
information set forth in its Press Release dated April&nbsp;30, 2008, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it
shall not create any implication that the affairs of CryoLife have continued unchanged since such date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The press release includes a
supplemental non-GAAP financial measure, non-GAAP revenues, which have been adjusted from the comparable GAAP revenue numbers to exclude revenues related to orthopedic tissue preservation services. The additional non-GAAP financial information is
not meant to be considered in isolation or as a substitute for total revenues prepared in accordance with GAAP. Combined cardiac and vascular preservation services revenues have been adjusted from the comparable segment revenue numbers to exclude
revenues related to orthopedic tissue preservation services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Non-GAAP revenues have been adjusted to exclude revenues from orthopedic
tissue processing because the Company discontinued procuring and processing such tissue as of January&nbsp;1, 2007 and is currently only distributing those tissues that were processed prior to that time.&nbsp;Because the Company&#146;s revenues from
these tissues will be reduced to zero in the near future, the Company believes that the non-GAAP revenue numbers presented provide investors with a more accurate measure of the relative revenue performance of the Company&#146;s continuing tissue
preservation business.&nbsp;Accordingly, CryoLife believes that this non-GAAP measure, when read in conjunction with the Company&#146;s GAAP financials, provides useful information to investors by offering: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the ability to make more meaningful period-to-period comparisons of the Company&#146;s on-going operating results; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the ability to better identify trends in the Company&#146;s underlying business and perform related trend analyses; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a better understanding of how management plans and measures the Company&#146;s underlying business. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information provided pursuant to this Item&nbsp;2.02 is to be considered &#147;furnished&#148; pursuant to Item&nbsp;2.02 of Form 8-K and shall not
be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor
shall it be deemed incorporated by reference into any of CryoLife&#146;s reports or filings with the Securities and Exchange Commission (&#147;SEC&#148;), whether made before or after the date hereof, except as expressly set forth by specific
reference in such report or filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Except for the historical information contained in this report, the statements made by CryoLife are
forward-looking statements that involve risks and uncertainties. All such statements are subject to </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">the safe harbor created by the Private Securities Litigation Reform Act of 1995. CryoLife&#146;s future financial performance could differ significantly from
the expectations of management and from results expressed or implied in the press release.&nbsp;Please refer to the last paragraph of the press release for further discussion about forward-looking statements. For further information on risk factors,
please refer to &#147;Risk Factors&#148; contained in CryoLife&#146;s Form 10-K for the year ended December&nbsp;31, 2007, as filed with the SEC, and any subsequent SEC filings. CryoLife disclaims any obligation or duty to update or modify these
forward-looking statements. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Section&nbsp;9</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01(c)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Financial Statements. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pro Forma Financial Information. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable.
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Shell Company Transactions. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">99.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press release dated April&nbsp;30, 2008</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">* This exhibit is furnished, not filed. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date: April&nbsp;30, 2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="text-indent:4.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ D.A. Lee</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Ashley Lee</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President, Chief</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="text-indent:4.00em"><FONT FACE="Times New Roman" SIZE="2">Operating Officer and Chief</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="text-indent:4.00em"><FONT FACE="Times New Roman" SIZE="2">Financial Officer</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Exhibit 99.1 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g2466402001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>FOR IMMEDIATE RELEASE </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Media Contacts: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">D. Ashley Lee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Katie Brazel</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President, Chief Financial Officer and</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Fleishman Hillard</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Chief Operating Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Phone: 404-739-0150</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Phone: 770-419-3355</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CryoLife&#146;s Earnings Per Share Increases 150 Percent to $0.10 in First Quarter of
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2008 from $0.04 in First Quarter of 2007 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Company raises revenue guidance </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>ATLANTA, GA&#133;(April 30, 2008)&#133;CryoLife, Inc.
(NYSE: CRY)</B>, a biomaterials, medical device and tissue processing company, announced today that revenues for the first quarter of 2008 increased 4 percent to $25.6 million compared to $24.5 million in the first quarter of 2007. Excluding
orthopaedic tissue processing revenues of $327,000 and $1.8 million in first quarters of 2008 and 2007, respectively, total revenues increased 11 percent for the first quarter of 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Net income in the first quarter of 2008 was $2.8 million, or $0.10 per basic and fully diluted common share, compared to $1.4 million, or $0.04 per basic
and fully diluted common share in the first quarter of 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Tissue processing revenues in the first quarter of 2008 increased 4 percent
to $13.4 million compared to $13.0 million in the first quarter of 2007. Tissue processing revenues increased primarily due to increased demand for the Company&#146;s cardiac and vascular processed tissues, and, to a lesser extent, price increases,
partially offset by a decline in orthopaedic tissue processing revenues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Combined cardiac and vascular tissue processing revenues in the
first quarter of 2008 increased 18 percent to $13.1 million compared to $11.1 million in the first quarter of 2007. Combined cardiac and vascular tissue processing revenues increased primarily due to increased demand for the Company&#146;s processed
tissues and, to a lesser extent, price increases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#151;more&#151; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g246642002.jpg" ALT="LOGO"> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Orthopaedic tissue processing revenues in the first quarter of 2008 decreased 82 percent to $327,000
compared to $1.8 million in the first quarter of 2007. These revenues declined because the Company discontinued procuring and processing orthopaedic tissue in the first quarter of 2007 pursuant to the exchange and service agreement signed with a
competitor in December of 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-Height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">BioGlue<FONT FACE="Times New Roman"
SIZE="1"><SUP>&reg;</SUP></FONT> revenues were $11.9 million for the first quarter of 2008 compared to $11.2 million in the first quarter of 2007, an increase of 6 percent. U.S. BioGlue revenues were $8.6 million and $8.3 million in the first
quarter of 2008 and 2007, respectively. International BioGlue revenues were $3.3 million and $2.9 million in the first quarter of 2008 and 2007, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Total product and tissue processing gross margins were 63 percent in the first quarter of 2008 compared to 61 percent in the first quarter of 2007. Tissue processing gross margins in the first quarter of 2008 were 45
percent compared to 41 percent in the first quarter of 2007. Tissue processing gross margins improved in 2008 compared to 2007 primarily as a result of fee increases and a favorable product mix in 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">General, administrative, and marketing expenses in the first quarter of 2008 were $12.1 million compared to $12.3 million in the first quarter of 2007.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Research and development expenses were $1.4 million and $1.1 million in the first quarters of 2008 and 2007, respectively. Research and
development spending in 2008 primarily focused on the Company&#146;s SynerGraft products and tissues, protein hydrogel technologies, and research on cold storage and preservation of internal organs. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of March&nbsp;31, 2008, the Company had $12.9 million in cash, cash equivalents and marketable securities (at market), of which $946,000 was received
from the U.S. Department of Defense as advance funding for the development of protein hydrogel technology for use on the battlefield. The $12.9 million of cash excludes $4.5 million of cash the Company used to pay off its prior credit facility,
which expired on February&nbsp;8, 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">&#147;We believe that the continued improvement in our core business, along with the recent FDA
clearance of the SynerGraft pulmonary heart valve and the private label agreement with Medaphor, Inc. for Hemostase MPH, positions us for a very strong performance in 2008,&#148; stated Steven G. Anderson, president and chief executive officer.
&#147;We will continue to focus on our R&amp;D pipeline as well as look for other opportunities to further strengthen our position in the cardiac and vascular surgery markets.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Financial Guidance </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-Height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s GAAP
revenues are composed of product and tissue processing revenues plus other revenues. With the recent clearance of CryoValve<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> SG pulmonary heart valve and the private label agreement for
Hemostase MPH, the Company now expects product and tissue processing revenues for the full year of 2008 to be between $102.0 million and $107.0 million, up from its previous range of between $101.0 million and 106.0 million. Other revenues for 2008
may reach between $1.5 million and $2.0 million, primarily related to funding received from the Department of Defense in connection with the development of BioFoam<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>. The actual amount of
other revenues is largely dependent upon actual expenses incurred related to the development of BioFoam. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company expects tissue processing revenues to be between $53.0 million and $56.0 million and BioGlue
revenues to be between $47.0 million and $49.0 million for the full year of 2008. Other implantable medical device revenues are now expected to be approximately $2.0 million in 2008, which includes an estimated $1.0 million in revenues from the
distribution of Hemostase MPH. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company expects general, administrative, and marketing expenses of between $48.0 million and $51.0
million, and research and development expenses of between $6.5 million and $8.5 million for the full year of 2008. The research and development expectations include an estimated range of between $1.5 million and $2.0 million to be funded by the
Department of Defense in connection with the development of BioFoam. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Webcast and Conference Call Information </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company will hold a teleconference call and live webcast today at 10:00&nbsp;a.m. Eastern Time to discuss the results followed by a question and
answer session hosted by Mr.&nbsp;Anderson. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to
10:00&nbsp;a.m. A replay of the teleconference will be available April&nbsp;30 through May&nbsp;7 and can be accessed by calling 877-660-6853 (toll free) or 201-612-7415. The account number for the replay is 244 and the conference number is 281786.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife Web site at <U>www.cryolife.com</U>
and selecting the heading Webcasts&nbsp;&amp; Presentations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About CryoLife, Inc. </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-Height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable
living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> SG pulmonary human
heart valve, processed using CryoLife&#146;s proprietary SynerGraft<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> Technology. The Company&#146;s BioGlue<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> Surgical Adhesive is
FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. Beginning
May&nbsp;1, 2008 CryoLife will distribute Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular, and general surgery, subject to certain exclusions.
The Company also distributes the CryoLife-O&#146;Brien<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> stentless porcine heart valve, which is CE marked for distribution within the European Community. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Statements made in this press release that look forward in time or that express management&#146;s beliefs, expectations or hopes are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated 2008 performance. These future events may not occur as and when expected, if at all, and, together with the Company&#146;s
business, are subject to various risks and uncertainties. These risks and uncertainties include that the Company may be unable to effectively leverage its existing sales force to sell Hemostase MPH, that surgeons may not choose to utilize Hemostase
MPH, that Hemostase MPH may not perform as expected or provide all expected benefits, the Company is dependent on revenues from BioGlue, the Company&#146;s strategic directives may not generate anticipated revenue and earnings growth, competitive
pressures and tissue availability may adversely affect the </I></FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2"><I>Company&#146;s ability to grow revenues, the Company&#146;s efforts to develop and introduce new products outside the U.S. may be unsuccessful, the
Company&#146;s efforts to improve procurement and tissue processing yields may not continue to prove effective, the possibility that the FDA could impose additional restrictions on the Company&#146;s operations, require a recall, or prevent the
Company from processing and distributing tissues or manufacturing and distributing other products, FDA and other approvals for products in development may not be obtained, and if obtained, may be costly and require lengthy review periods, products
and services under development may not be commercially feasible, CryoValve SG may not perform as well as expected or provide all the benefits anticipated, demand for CryoValve SG may not reach anticipated levels, and accordingly, the Company may
choose not to process the majority of its pulmonary valves with the Company&#146;s SynerGraft technology, the SynerGraft post-clearance study requested by the FDA may not provide the expected positive results, pending or future litigation cannot be
settled on terms acceptable to the Company, the Company may not have sufficient resources to pay punitive damages (which are not covered by insurance) or other liabilities in excess of available insurance, the Company may be unable to obtain
sufficient financing to fully pursue its strategic plan and future healthcare policies, healthcare reimbursement methods, and healthcare reimbursement policies may affect the availability, amount, and timing of the Company&#146;s revenues. These
risks and uncertainties include the risk factors detailed in CryoLife&#146;s Securities and Exchange Commission filings, including CryoLife&#146;s Form 10-K filing for the year ended December&nbsp;31, 2007, its most recent Form&nbsp;10-Q, and the
Company&#146;s other SEC filings. The Company does not undertake to update its forward-looking statements.</I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Financial Highlights </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(In thousands, except share data) </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>March 31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services (including write-downs of $146 in 2007)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General, administrative, and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change in valuation of derivative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other (income) expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income applicable to common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Weighted average common shares outstanding:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues from:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cardiac tissue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vascular tissue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Orthopaedic tissue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">BioGlue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other implantable medical devices</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Domestic revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">International revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Financial Highlights </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(In thousands) </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents, marketable securities,<BR>at market, and restricted securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,885</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,447</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Trade receivables, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,540</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,311</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,423</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,373</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred preservation costs, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,800</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,903</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,679</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,607</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">90,879</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">92,684</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Shareholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66,222</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">62,627</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For additional information about the company, visit CryoLife&#146;s Web site:
<U>www.cryolife.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><I>END </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2466402001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2466402001.jpg
M_]C_X``02D9)1@`!`0$"6`)8``#_X0!:17AI9@``24DJ``@````!`&F'!``!
M````&@`````````!`(:2`@`F````+`````````!&:6QE('=R:71T96X@8GD@
M061O8F4@4&AO=&]S:&]PJ"`T+C```/_;`$,``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`@(!`0(!`0$"`@("`@("`@(!`@("`@("`@("
M`O_;`$,!`0$!`0$!`0$!`0(!`0$"`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@("`@("`@("`@("`@("`@("`@("`O_``!$(`(4!60,!(@`"$0$#$0'_
MQ``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#
M!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!
M`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<`
M`0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[\****
M`,_5M6TO0-*U/7=<U&RT?1=%T^]U;6-6U*YALM.TO2]-MI;S4-1U"\N'6.TL
M8+2&:665V5(XXF=B%!-?D[^R9_P7/_X)C_MN_M#ZK^R]^SI^T7;>+_BW:1:Q
M/X>T[5/!_C#PEHOQ#A\/Q7%SK3?#K7_$^C6MOXJEM["UN;KR8F6>:TMY;NVC
MFMXI9$^]OVJO`W@OXG_LR_M`_#/XC>.[7X7^`OB-\'/B+X!\7?$:^U>PT&S\
M#Z#XR\*:IX=U#Q/<:QJMY;VUA%9P:DTY>>>*(^3M>158D?Y2W[-'[(]Q^Q9\
M8?CA^V5^SQ^WM^Q1^T7\0?\`@G187GQJ^%_P]^%>N^/_`!3XN^-ITC6+3PH_
MB.P\):GX:T>*X\!:+IWB*76?$KV&K:D(=/T>XB#M9S'4HP#_`%Y<?KR/4@8R
M<>G(_.EP>.#STK^#[_@VJ\%_\%"O^"@W[5'B7_@KS^T'^WQ>>*O"_A/5/'_P
M-\4_`Y=1?7=4\60:OH5AJT7A+4/`=JUKHGP;^'-GJ&J:!J^DG3[5[F[NO#X\
MJ**,W$\GP!_P4F^(W_!6;_@@=_P4,O\`X@^%_P!O'3?VBK+]M3Q/X]^*S_#'
M5;K6+[2/$.G:GXB;2CI7Q#^!.J:C/;^`Y5.NP:?H&K:!?0F9=`DBLY[9+&6S
MC`/[4/"'_!<[_@E_X[_;&NOV%/"_[3F@ZC\>X?$M]X&M(CH7B2V^'>M?$#39
MWM+[P%H/Q/N=,71-6\4K?13VL445V8;J\A:SM)[BZ*PM^M]?Y2_[)_\`P2/^
M#_PY_P""O7P>^%'Q=_X*;_L8:;I'PP^*_@3XN:TVD^/M:T_XE:EXJ\,>(-.\
M:1_!?[+J>AMX=T#XICQ!8+IVHV[^*;AK0"62W-Y=A+-O]6C(;YAR&Y!'((/(
M(/<>_>@`HHHH`*\<^,?[1'P"_9WT6+Q%\>_C7\*?@OHEP)#::G\4?'_A?P-:
MWQBQYJV#^(]3M_M\BY&5A#L,]*_FA_X.)/\`@X2F_P""<$,/[)G[)K:%K_[8
MWB_P]#K7BSQCJMO:ZWX>_9V\)ZQ&3HU[<Z+*S1:W\3]2MBUSIMC=*UI86:QZ
MCJ$%PES9VT_\`OP=_9>_X*:_\%B_C-XI\5?#[P9\;_VO?B5=:F)/'GQ1\6ZY
M+=>'?#UUJ,L<RP>(_B+XWU2VT?PQ$(YXWAT\74)2!0+6T\M54`'^M#\./^"O
M?_!+KXM^*K;P3\//V^?V6/$?BJ]60V6CQ_%_PIIT]\8B`\=E+K%_;Q7DV2-L
M<;L[YRBL*^]O"OC+PAXZTLZYX(\5^&O&6B"\N]/;6/"FNZ7XBTI=0L)?)OK!
MM0TBZFA%Y#-\DT6_?&WRNH/%?Y)_Q3_X-<_^"T/PM\'7WC*?]E_1?']IID#W
M-]H7PN^+'PX\:>+X[>*/S)6LO"UKK\=WK<P0,!!IZ75PY7;'$[%0W]PO_!J)
MX1\3^!/^"17A3PEXT\-:[X/\5Z#^T+^T%INO^&/$^CZCX?\`$.B:G:>+K>WN
M=/UC1]6MH;BPOXWCVO'+&'0C:P#`@`'])]%%%`!1110`4444`%%%%`'FOCKX
MS_!WX77-E9?$WXL_#/X<WFI6D^H:=:>//'GA;PA<W]A;3Q6MS?64'B#5;=[J
MSCN9X(WE0,B23(C,&8`V?`_Q;^%'Q.EU6#X:_$_X>?$.?0ELVUN'P-XU\-^+
M9=&744DDTYM5CT#4K@Z<MQ'#*T)F">:(F*;@IQ_%+_P>\^&K6?X'?L$>+QI^
MF&\L/BS\9?#<NJ-!;_VP+75_!WA+5(-/BN3'YK:89M$N)9(P_EK*L;%2S`CZ
M1_X,N?"_A"Q_X)Q_'CQ;INB:3;^,]>_:S\3Z-XG\00V:+K6IZ/X>^&_PWN/#
M.E7]^5WSZ=9R:WK<EM"&\N*35KEPH>9RP!_852X/H?RI!U&>G>O\H#_@L/\`
MM_?\%;/`/_!8_P"-NDM\:OVC?AAXO^&?QUFTK]FCX4>!_$'C#2/!T_PYBUL0
M_".7PI\/])=+#Q]8:]HPT^>YEEL[TZO=:G<P7'F'=!&`?ZO]9VJZQI&A6J7N
MN:KINC6<EU:V,=WJU_:Z;;27M].EM96:3WDJ*]U-<R1QQ1@[Y'<(@+$"OYK_
M`/@OU_P5>_:*_P""<W_!-3X(^+O`.DVG@/\`:Y_:C7PKX$;6WLK+6+#X*ZY_
MP@-KXM^+.KZ79:A#);:CX@L[MVTO2A/%)#%-J)OGBD^R")_X.OV'?A-_P5F_
MX*$?'SX8_M,:!X?_`&KOVO/`OP7_`&E_A!XQ^(WCG7?%/B/QWX>T36-'^('A
MKQ)?);0>+_$0M]3U:WT^074UGIT<LEG:3"::."V.^@#_`&)J*5NI^II*`"E(
M(Z@CZU^(G_!;KXP>/OAY\%_#GA;P[X^UWX8>%O%/P\_:C\;ZCK7A_7]3\(7W
MQ0^)GP4^">H>//@K^S0WB_P_JECJNB6?C+Q2E_=7<&CWUEJNM6/PZN_#]I=1
M'57W?!G_``21^(_[5O@C]J71OA+\9GUWX3ZIXK\<_&7P1X__`&4?%H\2S:K8
M^!O#/P`^$OQO^'W[1MKX>O/B;XSTSP#>)XN\;7WA:\GT#Q`VCZO:>*])@U.T
MM_$6G/&H!_5;4,5Q;SR3PP7$$TULRK<Q13122V[."R+/&CDPL0"0&`)`.*FK
M_)\_X.GEU;X4?\%F?C__`,(!XCUSPG:>._AY\$/'>L6'A?7]0T>VEU_4?AWI
MFF:E>W=II5Y&%OKB?1C<RF1?,D>]:<Y$H)`/]80@@X-)7YG_`/!&B*WB_P""
M4W_!/U[=)5^V_LL_"C5KM[B^O-2N;G5-9\.VVK:Q?7-]J$\DUS=7&JWMY/*S
MN3YEPP&%`4?IA0`4444`%%%%`!1110`4444`%%%?R*_\%U/^#E;XA_\`!+W]
MJ?0?V3?@%\`?`'Q.\6Z7X$\+_$'XF>,?BIK'B.#1;.+QC+=W&A^$O#.B>%KR
MTF:_&C6*7-U?W%TT2_VK###:,T<DE`'T+_P4^U7_`()_?\%IOB3X@_X(MV?[
M6?Q.^#O[7OPJ\?0^/=2TWPS\.?B-=^&2G@C0+;7O&7AWQ(]VNF^&_'M@_@W7
M#/:QRZFXM-2M+>ZMQ));RP2_S-?\%Q/^"&WAO_@B_P"&?V6/VT/V+-3\>^-?
MAOX9U*#X7?M"?\+*U:#7;F^\9:Y9WT%IK6M6^CZ?9Q6'P[\9>&[GQ1X<U?3H
ME2V@$UM:H[OJ9(\$E^)O_!4BX_;GL/\`@O!^Q7^SKX8LK#]LC3?&.J^`8/$>
MO^"/''A[0M430A\'?BUX+U'2=:\3:'?3WUGX@\%:S-8W)MXHY;&[M)@[R?:8
M8_6_VE?^"L7_``7G_:N^&/C+]D;]I?X`?`G4/A;\=;'1?`/C'3K3X6>$_P"T
MUTWQ9?Z<VD:WX8U.+XFW<=IXAMKEK*_TN]BCF:UN[&&Y0;H>`#Q?_@AO^V]X
MC_X)I?\`!1>R_P"%.^#OC)\?/V-_VP_AS'X@U_X9?!KP5KWQ4^)FEZ%96^L7
M?A^]M/!VB027.J>//`/Q"&O^&M7D'DB\TZ6[OU/DWM@3^=/[;O[7'[17[6G[
M7'QZ_P""FOQ;L6\!:YH'Q@M?A]\'/AYXYL9UU3P5K'AZUOSX&^'>A>'=1@7_
M`$OP+X9M[+6=;FFA$*:W?V;7B"YUN,-_K,_L1?\`!/[]E3_@GK\(]'^#O[+W
MPKTGP'H5B+F[U;6[BZN_$7C/Q-K>JV^D1Z]K/B'QAK4DMY?7-Y)H>E-+$CPV
M:G3X1!:PI%&B_EU_P<%_\$W_`-GO]I;]C;XF_M+3_`ZT\:?M/_LO>&-0^)?P
M2O\`1I%L(==UN+Q%X=U37/#?Q#\//J-KIOCCP5J4.FQ_VO'?C[6;2U<VEU%(
M`K@'\WW_``36_P"#4/PK^VA_P39TG]H#]HKXJ?$KX*?M1_M`7S?$KX.:C'I\
M.OZ'X.^%]U%(OAAOB-X'U2:VG\37_B822ZS)-'J-C=6EE?Z:8W,ANX9?ZL_^
M"3?[5G[$6GZ0_P#P2N_9]_:&\=?'?XZ?L#^!)_!'QJU?QWX4^)5AJ.I:[X-\
M5?\`"'^.M<@\4>-=/-KJ-D/'U[=0VMC97]U#86;6]I:%K2V1A_'%X9_X.0/^
M#@C3[QM#T;X"_`?6K3PQ;6^G2>'-#_9^NIM+TFS2%K73;:#_`(17XC`6EI%'
M;;($BD$06#8H(4`>%?L@_M=_MI?\$9_%7[07_!6/]IS]G.W\0_%'_@H=J?Q`
M\`_"+P?KOBG2O"7AGQ!XWNOB!X=^+WQC^(GB?P[X8N+V^T3PGI;7>G6.FZ>P
MM;NZN]>:-7AM[:6X8`_U-*\W^,GQ.T'X*?"+XI_&3Q2P7PU\)_AUXU^)&ODR
M+%G1_!'AO4O$NHHLC#"NUKILJKP<LX`!)`K\;?\`@A'_`,%GHO\`@L1\%OBO
MXD\2?".W^#?Q=^!7BKP_X?\`'V@:!JNI>(/`^M:9XRL=4U#PIXD\+ZMJ=E%-
M:/(-#UJ"[TZ=[B:U>PCF^T217483[J_X*C^$=?\`'O\`P3:_;R\'>%K%]3\1
M>(?V2/C]IVCZ=&2);Z^D^&GB-XK6$*I+SOL*HH!9W(5020*`/\A#PCI/QL_X
M*Y_\%)M&TS6-5EG^,'[;?[1\3:WK3K-J5OX5M?&WB`W&JWT,#N&?P]X<\&QS
MF"'<JQV'AV.%2BJ,?[)7[(G[)'P+_8;_`&?OA_\`LT_LZ^"]/\$_#3X?:8MK
M:V]M&KZKXCUN=4?7?&?BS5"OFZ_XMU.^5[B]O)V9W=UB3R[>*&*/_)1_X-XO
MB)X=^&'_``67_8-\1^*+A+32M2^)^K^!8[F61(HHM9^)/P_\7>`O#OFO)P$?
M7_$.FQ]N9AR*_P!D/I0`5^8/_!9']IOXT_L6_P#!.']I/]J+]GC4_"&C?%/X
M/Z3X3\3Z._C3PI_PEWAS4K:]\>>&/#^MZ=?Z/%JEDS3SZ3JUTL5P)\PRI&Y2
M104/Z?5^('_!R!%=R_\`!%3]NL6ETMHR>!/!4L[-`EQYUI'\6/`;W-J%=AY;
M2Q!D$@YCW;@"1@@'\;/PO_X/,/\`@HQX:\._$BV^*/PH_9V^)GBC5O#,=C\*
M]6T[POKW@?1_!GBJ35+-[OQ!XOTFP\27$GC32TT1;^.WL+>XTMOM4T4T]W)%
M&T$GZ2_\$,O^"PW_``52_P""L'Q\_;+\`>(/C_\`#CPE\2/"7['NH^,_V=O#
M4/P<\-#X*>'OB7IWQ,\$6$6K>+]$M9DUC6;>ZAU2/3)I9=8F>TM-<N+FWB:6
MWAB;\)O^#8O_`()J?L[?\%'_`-MSX@:1^U#I-WXR^%_P!^$T7Q5/PSBO;[2]
M)^('B2Z\8Z%X;T73O%=_IES#<OX6MEO;RXN;.&6(WLB00S.;7[1%+_J!_!7]
MC/\`9(_9OUR;Q/\`L_?LT?`WX*^)+GPNO@J[U_X7_#+PCX(UF]\)KJ%OJP\/
MW^I>'M*@FOM,_M.TM;@QS.X,UNDARR@T`?Y_7P<_X.J_^"H_A;]LOP#\`/VQ
M8?V=_ASX)T?]H[PE\)OVBKFR^#&J6/BGX>Z!I/Q!MO"/Q0-F\_CUX;>_MK>+
M4V>::*=8?LYEAC*A4/\`I+PS0W,,5S;2QSVUQ''/;SPNLL,T$J"2*:*5"1)$
MT;*RL"00P()!K_,C_P"#OW_@GBW[/W[9'A3]MKP'H26GPN_:^L'LO';V-NZ6
M>C_M`>#+"*#79KME8I`_B'P@FDZE']UKB^TC692"0S']R?\`@G)_P7E\+>`?
M^#>/Q)^TO\4M?L/$/[0'[%VBK^R]:^&=4U(7&M?$+XCKI=MIW[.%Y?PN/.GL
M]1\.W>EMJ,YW/)'X%UVYW%H7P`?*G_!=7_@Y*_;*_82_X*&>./V9?V.O%OP"
M\4?#SX;^"O`B>-[;QA\,KOQ3K'ASXJ:I9W>I^*?"-UX@M?%ULM]]GTN?P[+(
ML<43VLVIS6<F9K9VKVCXP?\`!S#\8/\`@G_^RCX#TK]K+2OAU\?/^"F7QJ\)
M:!\7%_9^^'GA:]^&7PI_95^'GQ!T"SUGX>:!\;-<&MZE?:[X_ET62UU2\T6V
MF@OXQKB6EP^FQ0PW=[_)%_P2I^!WB']NG]N/XO?M6_M#17_Q'^'?[,'@WXO_
M`/!0?]JC5M8D#P^/=1^'L.K?$31_!6K7D[!#)XJ^),5A:RVY(,FF1ZD(P%A)
M7-_X)B?LG>,O^"V?_!5;2O!OQN\8:Y-!\7?%GQ"_:%_:4\:Z=,L>O2>$M/O)
M/$OBRUT.:6*2/2[K4-8U32-%L&$9AT]-7B:*(QVR0D`^QO%G_!VQ_P`%F_$7
MB6YUW0_BO\'/`FCFY%Q%X-\,?`3P%J/AZSMQ(0MJU_XPL=4U66-E95=I-1W%
MCE#&V,?N-_P2R_X/"%^(_P`0O#OP7_X*8^"/`WP[M/%-]8:-H/[3'PMLM6TK
MPAHVJWLIMH!\5?`]_?7SZ/HLMP]N'UG3;G[/9;R]WI\=J);J'^Q_X,?L5_LE
M?L]?"W3/@M\'/V=/@]X'^&>F::FE_P#"+Z=X"\.3VVK0"$0S7/B6ZO["6X\4
MZI.HS<W>HRW-S<L2TTKDYK_/=_X.Q?\`@D3\"/V*_&'P=_;&_9>\(:/\+OAO
M^T!XHUKX=?$SX3^&[6.P\'Z!\5;#2;WQ9I?BSP=I22;-"T_6M`M-:6[TVUC2
MQMKKPX+BW2'[:\8`/U-_X/8K_3M0_9#_`&&KRPE74;?4?V@?&=_INK6$L%WI
M5QITWPNDE26&\AE*SI<1W%I+;O'NCDCB=]V`F[TG_@RFU))O^"?_`.U%I(C8
M2:?^UW?7CRF6!DD34_A%\-HXT6%9#)$5.G2$ET57\P>66*OM_EB_:Z_:X\<?
MM4?\&_W_``3]\/?$'57U?Q!^RK^V?\7?V<+34;B266_U3P+HOP3\+>+?AQ)J
M$DDA,L]AX=\32Z/&QQFVT"#DN9*_JJ_X,JX[8?\`!/#]I66.U:.Y?]L+6TN;
MQA!_I*Q_"'X6&"!2@\PI$))#^\)7-R=F,O0!_8[7\!O_``44_P"#GS]J/]DO
M_@H3\=/V<1^R#^QSX_U3]G?XT:AX`\!_%/Q-H?C^3QE#X/E:QO-.":A)XA\S
M2=6EL-4MWN9K-HK?S_,:*W>,H3_?E7^.C_P<$PQ6G_!;G]N06\:1`_&OPE<L
M$10K3W'@/P%<32E0N"[3.S,2"6+$G))H`^F_^#A'_@LW\3_^"BWQ+U#]EWQ-
M\+OAQX.\`_LF?M%?%Z#P3XO\)W/BJ7Q'XRM8)9/!-I+XCMM>O7@M919:;)*Y
MMXHP\L_RJB(`U_\`X(Z_\'%GQQ_X)C_!OPU^R%X3^`7P>^(7P[\2_'E_&^L>
M,O$^H^,M.\8V-MX^N_".A^);>"+0]06UO)(-,T3=92/#NCDD`E6>-%CK[^_X
M.NOV$OV/OV3/@Y^Q+\2_V>/@'X2^&'Q(_:"\?_&#Q-\7O&^C:AXHO-;\;:G+
MX9\#^*+Q]5_MO7;J$QR^(O%>J7>V*.-87?R[<10DQUV7_!&_]BW_`()WZA_P
M04_:1_X*#_M*_LG^"_C+\8_V>O%W[0_B[P_XNU'5?&>E>(II_A7X7\'^(_A]
MHPNO#WB&W2+3HO$MU`)!Y#HT,\HN(YHRR,`?T$?\%GO^#C[]GW_@EOJLGP-^
M&OA6S_:/_:WELK2^U7X=PZ_)H?@CX2V&HP1W>G7GQ4\1V5I/,-<N+.6.:WT&
MR47SP2)/>7&G0S6SW'\G=K_P>6?\%38O&3:Y<?#_`/9(N_"CW*./`_\`PKCQ
MO!`EJLFXV\?B&+XE?;?.:,E3(S,!@,(P<@_AQ^QEK?[-?[1'[?WA#Q__`,%1
M_C/XHT'X%^./'OBKXF_M%?$!=/\`%_B7Q+XVU6:WU7Q-_P`(W/+X-M+G5--C
MU[Q1]CL;F^M(B]C:7DKP&)DB=/[M?'W_``4V_P"#1N_^"S?L]ZAX0^!5[\+]
M0\.W/AV'3_!O[&'Q.M->T:S$`MDOK'QQIWPJ@UO2O$:^9YL.IQW_`-O\Z/SC
M<&0;B`?:7_!,S_@KM^PY_P`'`OP?\6?LT_'[X.^'?#7QNT'3=,\7^.OV<O&6
MHS:WHVNV7A[4K.?3OBI\$_&L"65\+G2M<-E+YMLUEK_A^XG@FCF>)DOF_<3X
M+_LF_`/]G_Q!XE\8_#/P5>6WCGQAI6DZ!XE^(/C+QKX\^*/Q"U7PYH4DLVC>
M&9?'?Q/\3:QJMOX8MKB>66+3H;N.R$[F<P&<F2O\<'X/_M%^"?V`_P#@IIX:
M_:%_8Z^)&N>.?@Y\#?VC)=;^%WC;6M$UCPSK/CSX&2:_+8WFE^*/#VIQVUU;
MSZC\.M1U#3K^&:.(R22R2"-`R*/]K;0]:TWQ)HFC^(M&N4O-'U_2M.UO2;N,
M@QW6FZK9PW]C<H02"CVMQ$P()X:@#4K_`"G_`/@[WDB?_@L/XE6*&2)XOV;_
M`(&)/(\#0K<3&S\32K-%(0/M2""2&/S!D!H&BSF,@?ZL%?Y3W_!WL;D_\%A_
M$XG\GRE_9P^!8LO+?<_V;[#XE9_M"[!Y<WVQKO`RW[O8V[YMJ@']^/\`P2^^
M*GPR^`__``1;_8C^+?Q=\9^&OAI\,/A]^Q;\)O$_C+QGXGO[?2-`T#1K#P18
M75[>W=Q)C=(3D1Q1J\]Q-*D,$<LTB(W\V'[9/_!ZEX6\,>-=6\)_L,?LMVGQ
M+\*Z1>W5G#\7_CQXAUKPOIWBE(0T46H>'?AIX;MX]0L]*DEVR0RZEJEM=218
M6;3K:0X7\W_^"\U]/:?\$5O^#?6RM]2UNVCUK]G[4$U+3;;6=1@\/ZM;:1\,
M_@[<VCZOH,<PM=1O[6\O=UI<2HTMNMW<+$0LSU][_P#!L%_P1$_8'_:@_8TF
M_;5_:H^&>G?M$^._&7Q'\?>`_#?@;QK>:DWP\^'FA>"+VSTMI7\+Z;=P1Z]X
MJOKAYKF2XU`W,-O:SVR6D$,OG32`&K^QY_P>JZ=XB\=:!X3_`&X/V5-)\!^#
MM9O=/TZ_^+OP'\3ZSK4/A4W5S';SZSK?PU\5PRW-_HD,;F:X:QU>6[2.)O(L
MKE]L9_NA\#?$/P+\3/`?A?XH_#_Q9H7B_P"'7C7PUIOC'PIXST/4;>]\/:[X
M7U>QCU/3M;L-21_+DL)+&5)-Y(VC(?:58#_/4_X.L_\`@CQ^Q7^Q;\&?@9^U
MG^R5\,;7X%ZEXL^+$7P:^('P[\(7-U_PKG7;?4O"7B3Q3HGBG3]"U&ZF;PWX
MBMY/#-U;S"R=+.\@O%>2VCN(3--^?_P0_P""J'QD^"'_``;7?%W]FK0?'NH0
M>*O'G[9&K?LT>`+RWU1HO$7@;X!^+OAQI?Q>^*>G:3,K^?;:7>ZE-K&EQE2!
M%%XZOEB9"L:@`_I*_P""E'_!WI^S=^R]X^\6_!3]C;X5#]K#Q[X/U&XT+7_B
MCJWB@^%/@3IVO6,\UMJ=EX<OM+M+G4OB1';7$1CDN+4:=I\KJQL]0NH@)#^2
M'A#_`(/:_P!KRSNV_P"$X_8P_9Q\3V3&01P>%O&/Q)\&WL;/"4MR]YJ5WK4<
MD:W.UG'V=2Z90,A(D7R[_@V+_P""$GP9_P""@.F^._VR/VQ=!O\`QA\`?AWX
MU/PZ^&7PD34-0T71_B=X\TFPT[6?%&N^,=1TBZ@N[CP?I5OJFDVT5C;S0C4+
MZ\G%U)]FLWM[K^QS]HC_`(-V_P#@D7^T'\-;_P"'Z_LA?#KX*:H80WAWXE?`
M/2[?X:_$#PMJ4*@6FH6FH:7$UKKD:.B[[35K2_M)1G="'VR*`?L3\/\`Q+/X
MS\!>"/&%S:Q6%SXL\'^&?$MQ8P2O-!9SZ]HMEJLUI#-(H:6&.2[9%9@"RH"0
M"<5UU9&@:1'X?T'1-!BN)KN+1-(TS1XKNY6%+BZCTRR@LDN)TMHDC29U@#.(
MT1`S$(JK@#7H`****`"OR,_X*&?\$/\`_@GO_P`%.?'/@_XH_M.?#;Q*?B9X
M.T=/#4/C[X:^,;[P)XD\0>%(+F2\LO#'BV>T@FAU[2[6ZN+QK1Y(1=VHOIHX
M+F.*1DK]<Z*`/\KZP_X)=?"[]O#_`(.$OV@O^";$OC+QG\%_V>?@B_Q/\+_#
M.S\$B/7+OX=_#CX.^&=*?PQX5\.6WBY[J&"TN=5OS<WUQ*'FO;S5;S4)WEO+
MR69_K_\`X*;_`/!M-^QO_P`$I_V5O'?[9>O?MO?%SQ!J_@75]"MO@[\,M;^&
M7@I9?B3\4M0U.*3P=X)N=1T[7H9!8/):7-UJEW;P(UKIFEWETD3/$D3_`-;_
M`/P6M^(?_!1'X`_LPVWQ8_X)9?`?PO\`$CX\6OC[2M0^*.N6WA'PSXM\=:-\
M*-(M)]4UH^'_``3J,*W'CRXU&^L-,L+V*T>;4+:PEFELH#<&*YM/\_+]OK_@
MHE^V%_P7"\>_#&^_:5^&%[\`OV>/V,_AKK?C+XZ6_@C3/%\?@W0[N"]2#QW\
M0[T>)[0G2/'_`(BN(_#7A/PQI%U-<^1J>HV]K%._VN^EH`_NX_X)\_\`!P]^
MP_\`M?\`PU^$US\<O&OA#]C+X^?$SP_K.OV'P?\`C-XQM-(TG6]!\.WESI%Q
MXU\(?$36+.QTNY\*:AJFDZ^NEQ:A-9:E.N@7ACM9X85NIOR;_P""\O\`P<#_
M`+&7Q$_94\6_LC?LYZKJGQX\"_M)ZNWP3^,7[2G@",S_``^^#>A:;XD\-ZCX
M^L_#]MJ=M%+\0_'TO@_[1<:3%#]FT:[@G-S;:M=&WG@3\M_^#;__`()@:9_P
M4Z_:B^)W_!0']JOX6>'=5_90^#[W/PV^%?P9\0Z5+K?P[\5>*O\`A%5\,^&O
M`6G6.K[DU+P%X"^'UQI?^L#F;5KG3)6+30WI'Y)_\%._^">=[_P3%_;Q^,/[
M%?C35O%D/[,/QQ$/Q"^`'BNT6TEMKRQOAX@A^"^M:W<:S:E)[OPMXQU34O#O
MB1[:2*[?3)M0N(6`O+96`/Z5?`'_``9@?LB_%/P1X0^)7P[_`."B_P`5/%W@
M/Q[X=T?Q=X/\4:'\*?`EWI7B#PWK]C!J6D:KI]U%XHQ+;S65Q"ZD@%=VUE5@
M5'YC_P#!"W_@F)\#_P!LO]K#_@I7_P`$V_VE+WQWX]_9\^`-[KNJ^"=;T7Q'
M<^#_`!/X2^*GP]^,UQ\,=+^)'A6V22[LM#UW6/!B:U::M"UK=VUY;B".X$C6
M5E)%YU^P=_P6A_X+"?LA_L[O_P`$A_V<?V9]>\3?M*>%OB'X@T7X9:UK_@7Q
M+XS^+'P@T'6]3&HZYX$T_P"&-]I<FG7MI;^(;C6+VQU;5'DTZPM=;FWVT]JE
MM+#_`*3_`.R);_%:_P#V>_@_XQ_:-^%G@WX4_M.>*?AOX5O/CYX>\(?\(]>V
MUM\1O[/B/B-#KGAV$07\<NI":Y\J.6>*V>\:WCGF$7G.`>4?\$^/^";O[*O_
M``3'^#-[\$?V5?"&K:%H&O>()?%GC/Q-XKUR;Q-XX\=>)I+:.QBU?Q1KLL,*
M2M!IT,%M;6]K;VMI;Q1'RK=9))I)/N>\L[74;.[T^^MXKNQOK:>RO+690\-S
M:743P7-O*A^]$\,CJP[AB*LT4`?XS/\`P6,_X)\?$C_@E%_P4(\=_#K28==T
M/X>7_BR3XR?LK_$2T2ZM(]1^']YKIUKPVFD:N`%;Q/X8U=5TJ_"/YL5UHL5T
M56&[MF?^YS_@D-_P=(_LB_M1?"KP7\,/VYOB-X:_9F_:K\.:19:#XC\4>-W_
M`+!^#7QAN]/@AM5\:>'O&;)]A\&:W?(HFO\`2-5DLXHKN20:9<7,#I%!^[7_
M``4._P""<G[,?_!3;X!:G\`_VE_")U2QBEN-7^'_`(^T0PV/Q!^%'C%[5K:W
M\6>!]<>)S:7&PHEY93++8:E`GV>^MYD$9C_SOOVQ_P#@T0_X*8?`KQ!K=Y^S
M9'X#_;"^&<=W/)H-[X8\2:%\./B<FF&60VR>(O`?C[5;6S&H+$(E<:7K&HJ[
M9=5C4[5`/]''XB?\%!_V$_A-X.;X@?$3]L7]FGPOX0_LS^V+;6;SXT>`+B/4
M]-,#W$=SHMI8:[-<:[YD2,8DLXIY)CA8D=B`?PY_X*R?MZ?L^?M]_P#!O+^W
M;^T7^SUJ_B;4/A->7*?"_0/$'B3P]<>'+GQ-J_A/XW?#_09M5TW2+F1[F#P]
M>7T\9M'NX[:Y:)]UQ;6S91?X5?`?_!N7_P`%H/'_`(A3P]8_L(_$/PVYO#9W
M&L^//$GPX\%>'K1TV;[AM7U_QA#'=60#KB6U$ZO@A-Q5L?US?`__`((Z?\%!
M?"/_``;@_M$?\$VM:^%/A2S_`&I_B=^T'?>(?#_A>]^*W@L>&8?!?_"Q?A3X
MD;Q+)XQT^^NK!8GL/!>L-#:>8EQ(TL6](F=@`#\O_P#@R69!^V9^V6AB!D;]
MF'PZR3;W!C1/BKH(DB$8^5@[/&2QY7R`%X9J_P!(JOXL_P#@VH_X(U?\%"/^
M"7O[6?QU\<?M5?"SP1HWPY^*G[/Z^#M+\8>$/BUX-\8/I_BW2_'_`(<UVRT:
MZ\/:7<F]=+K3+?5)#<B(6\!LXT9V>;:G]IE`'Y=?\%EOV$+/_@HO_P`$[OV@
M?V<[33+6_P#B,WAR3XB?`^XN`5DT_P",W@"&YUKP8EM/YJ"V.I$7^B3R,VQ;
M7Q/.7#+D5_B^:G'K^@R:OX2U<:MI#Z=K4D>N^&[Q[NT2U\1:$U]I<@U+2I&5
M5U:T:XU*W#21^;#Y\T8*AW!_VW/^"EW[;'A+_@GG^Q'\??VK?%4UH]Y\._!E
M[#X`T2ZD1#XL^*GB%3HGPX\+0QOS,MUXIO-/-SM#&*RMKJX*E(6Q_ER?\$/?
MV(?%W_!6?_@JCX:N/BQ;3^+OA]X>\9ZQ^U+^U7X@O+3&GZ[IT'BH>(KCP[J+
M0(L4=QXI\?:G9:>8%VL;.]OYHT,=K)M`/[2?^"''_!'P?!O_`((F_&;P/XVT
M*'0OVAO^"D?P,\=ZOXVO=0BDM]5\,>%?B'\.==\/?!'P=?&1@UHFGZ)XA75[
MJ'",E]XKNH9P6@`7^(7_`((S?ME-_P`$B/\`@JEX/\??M"^'O$'AOPSX5U3Q
M_P#LY?M'Z)]CN!X@\%:/KEXOASQ'J=UI"V[37TN@>+M$TG4;BTB3SYXM$EB@
MW2NBM_L:0PPV\,5O;Q16]O!''#!!!&L4,$,2".*&&)`%CB5%554`!0H```K^
M3S_@NI_P;/\`A#_@HOXLU#]J?]DC7_!OP5_:RU"$GXDZ)XHAO[+X9?'IK.Q6
MWTW5]9O='MIY?!OQ&CCM[>!]4CL[FWU.%(UU"*.>,WS`']/?PN^-'PA^-O@7
M3OB=\'_B=X$^)GP\U;3X=5L?&?@GQ3HWB+P])8SVJWJRS:EIEY)'9NMLX:6.
M8QRPX9941E8#_/>_X.^/^"H?P`_:3U/X(_L-?L_>+_#GQ2/P/\=ZO\5_C)\0
M?"6J6NM^%]'\<R>'M4\&>'?ASHVM6#/;ZMJEII>L>(+K6'MY9H+>6\L;3S!=
M0W<47XSZW_P;O_\`!<SX<:]JW@;2OV.OBA=VES<_9;K4/A]\3_AU?^"M<28F
MS%TVIZ7\08[>:T>+(8W2Q.D1_?(B\5^WO_!+;_@S[^,FJ?$+PS\5_P#@IUJO
MAGP-\-/#6IVNKC]FOP#XFM/%GC'XAR6CV]S!I7CSQQX;NGTWPEX3ED#I>0:7
M=7^HW<0>!9]-9A.`#\./VCOV=O$O[/?_``09_82\3^,]`N]'UO\`:Y_;9^/?
MQ^\/M=DQ3-\-O#'PC\#?#?P9<S6C#*1Z@T&K:C:..'L[Z&;D3)C^J3_@S4^-
MOPA\#?L'?M,>$_'7Q,\`>"->3]K*]UN'3O&'C7PQX:O+W3=6^$WP[M;6[LK/
M6=5AFN+?[1HM^AD$?EEH6579DD"_3_\`P<K_`/!*;]L7_@H1\,_V,_@U^PM\
M#O`FJ^!_V=/^$[U"_2[^)7@CX:V&@V6I:+X,\'^$/`OA;PUXAGM8FL;;1?#T
M\OFK/%!!#!#;QHSDX_D=/_!J+_P6T8Y/[-G@`GIS^T5\#?\`YN*`/]2?Q1^U
MU^RGX*\/:SXL\6?M*_`;0/#?A_3[G5-9UC4OBWX#@LK"QM(S)-/,_P#;I)^4
M85%#.[,J(K.RJ?\`)?\`^#A-[*;_`(+:?MJW6GW)O+2_^*7P]U&&XV!$E2^^
M&?P[NE>`ACYML5D4QR9'F(0V!G%>\+_P:G?\%M+&2WNU_9G\#2M#=V3!+?\`
M:(^!;RC==PIY@#^-B!&@;>Y*MM1&;8^-I^YO^"B?_!OU_P`%H/VT?VW_`(U_
MM3>'_P!DKPKX<T#X@^(_"UQH.@:U^TK\`;K6(M'\$>$/#'@S3I=1NK'Q=%"M
MY>6_AA+IU2("$W_E?,8RQ`/OC_@]#5?^&9/^"83$OO'B'XN*H"`QE6^'7PE+
MEY-V5?*IM&#N!8Y&T`^O?\$'/V??$W[3/_!L+^V%\`O"L-Y'XJ^,FM_MA>&?
M!B+!O;5?$-WX%\)0:#:62-@31W&O:=%9DYXD,BY&WCVO_@Y,_P""=?\`P4,_
MX*/_``E_8`^%_P"R[^S3-XG?X7Z7XF\6?%N[U'XN?"7P_8^#/&'B7POX'\-V
M?@RX77_%5J=;GL3I.NO+J=BTUBR2J(6D+DI^BG_!N1^QM^UG^P-^P%J7[,W[
M7WPSL?ASXY\-_'#Q]XL\+?V3X]\$^/=,U[P;XVL?#FHQ7,5[X+UB\33;J#7[
M?7(I(+ADD8-'*@*/A0#_`"Y?V$?@#\"_CW^V%\+_`-GG]K3XTZQ^RS\-_&WB
M/5O!/B7XIMX=T_4I/`OC$6.H6OAO3O$MAX@U&SAT33+CQ?!8Z;>WES($TXWO
MG7"K%'*Z?V]6W_!D9^SU=*MW!^W_`/%Z[L+J"WGL9;7X.>!I$DBE0R"X6[C\
M7NEU!)&\31E%4!<G<X8%8/\`@O=_P:]^./VAOBKX[_;7_P""=5IX?N?'_C^[
MN?$WQF_9BU"[TSPK;^*/%<D'F:QX]^$_B#4[J'3[37-3FC>XU/1;Y[6&YOIY
MKVRO/.N6LC_-QX8_9._X.6OA?HEE\#O!/P\_X*D^#?"-DEUH.F>"?"/B3XQV
M/@>PM/L^9['3)=%\0?V79Z5]G^XT,R6Q7_5M0!_0KX9_X,V/V-?&/BOQY\//
M"W_!3?QIXH\??"V30[;XE^%O#_PX^&VI:WX#NO%-I=ZAX<MO%NBV7C>6?P]<
MWNGV=S-;PW1CDFBMVD0;,&O[$/@UX^^`7[._PQ^&O[-OB3]J?X5^*/&?P)^'
M/@CX6^(-0\7_`!&^'V@>.]4NO`_A;2-!_MCQ7X777@^AZQ=6UI;7,\#(-C78
M()5E8_SK_P#!J'^PM^VM^Q?X'_;=N_VT/@SXV^$7B3XR>.O@QXC\+R_$'4=(
MU3Q)XP72M"\>R>(-5N[O3]4O9VEBN=?L!.+R<3K<7<BO#'()"_\`*;^V/^S/
MXA_X*Y?\'(W[2WP"^!VEOI%AX]_:9U#PKXR\01P0QVW@[P+\%M#T#P5\7?B7
M?>7%Y>`O@_6[NW#@M>7^JVEMN>:Z7<`?ZPFC:UHWB/2[+7/#VKZ9KVBZE`MS
MIVL:-?VFJ:7J%LY(6XL=0L99(;N`D$!XW9201GBO\H;_`(.U-8CU/_@L_P#&
M.S2TO;9O#WP<^`.CRS74LCP7\DOP[LM=%YIJ/Q!9"+6HX"B?*;BRGD^\[5_J
M;_`WX*_#C]G'X._#3X#_``A\/P>%OAE\)/!NA>!/!6@VYW"QT+P_8Q65J;B;
M:#=W\IC>>YG8;[BYN99Y"7D8G^`'_@OG_P`$3O\`@J5^WU_P4[^.7[0_[.O[
M(=QJWPDU70_AKX-\->++_P"+WP9T>;QJ?`_@31M`U#Q4FBZUX]M[O2+.6^@G
M@@AN(8Y3!IL<SHC2E5`/ES_@O?`?^'.'_!N[<^=+@_LY^*8/L^(_)R/AI\"I
M/.SY>_S<-M^]MP/NYYK^IG_@TH3;_P`$8/A*V6/F?&7X_OAMN%Q\0+N/"84?
M+^[SSDY8\XP!^17_``5F_P""0O\`P4H_:F_X)R?\$:?V;/@Y^R[J'B#XF_LG
M?`GQ%H7QVL;CXH_![2M/\'>*;OPS\,?"UIX=AU+5?'4$6OW$DOA'5+D3V+3V
MRP-$'E$KM&G[\_\`!N?^R'^T3^PW_P`$U?#'[//[4?PVO_A=\5_#WQ?^+&OW
MGA^Z\5^%/&%I=:)XKU>RUC1=5TG4?!VN:A:6MB\$KQ/;M,LRW-G<2O&!,K,`
M?FW_`,'HDLJ?\$TO@9$D,4D<W[8?@P2RO;K+)`$^%GQ8=&AG*DVQ9P%8@C>#
MM.<U_$3X+_9X\7_$3_@B3\9?C]HFFR7VB?L]?\%#/`]OXDFA&YM-\._%3X(6
M_AG4]4F55)^RQ^*++X=6[,Q`5M80C@N1_H@_\'-?[$?[4_[?O["WPV^!?[)/
MPNU/XJ?$&S_:-\*>/M8TBV\4^!O"6EZ=X6\/>"O'NG76H:MJ7CC7K".4G4==
MTZ."*VD>5GD9G7RT.?E+_@W:_P""3G[0/[._[$'[<W[&G_!2/]F^U\,>"/VB
M?'6GWXT#4/&/@7QEIWC;P?XB^'L/A#Q%:QW7@?Q-J!T;4M/O-!T^XMYI/(GB
MGO(;FV<R0!D`/`O^#.;]OGX(ZY^RIXP_X)_^(?$V@>$_CW\.OB;XR^)O@CPU
MJM];Z=??%/X>^.DTV_U*_P#"ZW++_;>N:-KEI?Q:A:0EKB*QO+&Y6-X5N'A_
ML[\6^+?"O@'PUK7C/QUXFT#P9X0\.6,NI^(/%/BK5]/\/^'=#TZ'`EOM6UG5
M;B*WT^T4LH,DLB*"P&<D5_ES_P#!0_\`X-=O^"BG[$WQ4U'XD?L3Z+XR_:?^
M">EZR_B'X?>,/A-J*Z?^T%\.8XKFXN=.L?$G@W3;RVU&_P!=L8XH%35O#BW4
M5QM6Y>#3W8V\?P_!^RU_P7[_`&PKG0O!?Q,^$W_!2[XV>"/#?B72#J/AOXO6
MWQOU'P=9?V=JMC-.UQI_Q$O(;"XDA$2D,=S(1E64G-`'^N]XW^*7PR^&7A%O
M'_Q)^(G@;X>>!4%H7\9^.?%>A>$O"R?V@GF6"OK^OWUO:J\\8)A4R[I`/D!K
M<\+^*_"WCCP_I7BWP5XE\/\`C'PKKMM]LT3Q-X5UG3O$/A[6+,N\0N]*UK2;
MF:VU"V\R.1=\4CKN0C.0:_C(_P"#M+]@G]OK]JCX>_L>^*?V9O`/CWXV?!OX
M0:9XJTCXE?!OX9V>H:[XET3Q[K5KH@\/_$:X\#:<SS^)M-70]-U33!<00SS:
M2\C*P6+4W<?=7_!J_P#L5?MB?L6?L%>//#W[7.C>*?AU/\2OC+?>._A5\$_&
M5T[Z_P##CP@_AW2=.U/4M0T8W,G_``B%QKNOV]U=MI3"*:+[$+NY@BN+V04`
M?TV4444`%%%%`'RY^V[XV^./PV_8]_::^('[-'AN+Q=\?_!GP1^(WB3X0^')
M;!]6.J^.](\,ZA>Z##;Z/&C'6KY;J)9+>RVL+R>&.V*D2D5_F*?\$PO'G_!1
M7_@K_P#M2>/?^"?7[0WQ_P#VA_B9\`?VF]#\87?[4%]XJ%YXLM?@]J/@:RU#
MQ]\/OBE9Z?K/DVO@K6M-^+_A_P`(VR6,+V5OJ$&IW&DM`1-&T'^L=6)I7AGP
MWH5YK.HZ)X>T+1M0\17::AX@O])TC3].O==OT3RDOM9NK.W1]3NUB^423L[A
M>`<4`?R0?\$/O^"7O_!8G_@EQ^V)XH_9Y\=_&_P3XU_X)CV/AGQ9XZMKZS.G
M:QHOC7QQKH_L[0-/\$>%=4G77_A'XY&JRIJ>O*'FT6XM=*:)9]0N;F"X@^-/
MB3_P0-_X*Z_\%0OVS?''QQ_X*C?'OP;9_"+X&^-O%^D_!'PEX.?19)?B9X%T
MG6KC5M"T'X6>%="=+3X2^#=>;3-#2\U;7[BZU]?/,EQ97TD"35_>+10!_E8_
M\$__`/@JC_P6=\:?\%E_@[X.\2_%/XKZ_P#$7QG^T+H?PJ^-W[/.KZ!;1^"-
M!^&MOXJ33/B'X3N/A^EC%;^$M%\-^%H]4GMKV,PSV!T6*[>[E;S&F_U3CC)Q
MR.Q]17.6O@[PC9>(;_Q=9>%?#=GXLU6V2SU3Q1:Z%I=OXBU*TBVB.UO];AM1
M<WENNQ,))*RC8,#@5T=`!1110`45\7?M6?MY?`[]CWQ)\*?!/Q+TGXS^+_'W
MQMMO'MW\,O`/P-^"/Q*^./C/Q-;?#.QT74?&EQ'H/PWT"_ET^UL[3Q%H[/-=
M""'_`$P?O,*Q7?\`@K^V[^SC^T+\*M(^,7PD\8:UXJ\(ZC\3;7X+ZI90^`O'
M=IXS\"_%F35K+0M2^'_Q+\!WGAY-7^'?B#3-5O[6/5QJ]G:P:9'(+J[FBM")
MR`?65%&.OMUK/&K:4VJR:"NIZ<VN1:=#J\NBB]MCJT6DW%S/96^J2:<)?.33
MGO+:YA2<H(FEMWC5BZ,``:%%%5[RY2QL[J^E5VBL[:XNY`@!=H[:)YG"9(!<
MJAQSUH`_S=/^#Q'_`(*10?&']H+X>?\`!/?X8^++74OAY^SJL/Q"^-T>D74%
MQ9:A\>-?L;VST+PU?7%O,PEN?#?@?4)&EBX\J^\;7,$RB>SPG]%G_!K'_P`$
MZ9/V*O\`@GAI'QF\<Z3'9_&O]M%M!^,OB#SHBM_H/PJ.F-_PIOPI*9(5:)FT
M'4K_`%R=.TWC+R7RUL,?;_[-7[$/_!(_]L_X1_#C]LSPC_P3Z_9SGM/C]I<_
MQ4M;_P"(OP*^']SXTN[_`,2:CJ$VK7OBR*6VO8KO6YM3-_).[37`D>7S-[%L
MC]<M`T#1/"NA:-X8\-:1I^@>'/#FE:?H>@:'I%I#8:3HNC:5:Q6.F:5IEC;(
ML=EI]O90P10PQJJ1QQ*B*%`%`&M117@GAO\`:&\(>*?VD/BK^S%INC>*D\:?
M"#X7_"CXJ^*?$-UIUK%X,GT?XPZU\1-%\,:/I.IK?M/=:]')\-=<FNXGMHXX
MH;FW*2RL[K&`>]T48(ZC%+@\>_3/%`"45PGP_P#B1X4^)VGZ[JGA&;6+BS\.
M>,O%7@+57UGPSXD\+3+XE\%ZM/HGB"&RM?$^E6DNJ:6FHV\JV^H6R2Z??1@3
MV5S<0,LA[S!SC!SZ=Z`$HHQSCOTKY1^!7[5>F?M"?%;X_P#@3P-\,O']OX"_
M9]\=:G\)-9^-^O2>%;#P-XU^+OAA[-/'?@;P)HT7B"77-2CT.6^AM[W5+G3;
M33I+R">UM)KAH68@'U=111S^/^<=:`"ER?4_G7RO^RA^VE^SA^VWX7^(7B_]
MFWX@Q>/M&^%?Q7\8?!3QXS:1K&A7N@?$/P1/!#K>DW&G:[96\TUHT=U;36EY
M&CVMY!<++;S2*&V[7P"_:T_9^_:@UGXWZ'\"?B'8?$*]_9T^+&L?`_XNRZ78
M:M;Z?X:^)_A^TM+S6O#,&I:A8PP:Z]LEY$DMS8/<6HF1XA.TD;JH!]&Y[_Y^
MM?DG^P;_`,$7OV0?^"=_Q_\`CG^TQ\$M1^+GB;XL?M!VNKVGCO7?BOXLT+Q:
MT*:_XQD\<Z[+H,EAX2T^;39KS7FB:Z)FE69+2(.I9`U?K97CGQ(^.O@'X5>.
M_@5\.?%LVKQ^)?VBO'FO?#CX;QZ?I<E]93>)/#?P[\7_`!0U,:W>)(HTBP'A
M?P3K929@X>X\F$+F3<H!['17GWPN^*G@#XT^"M.^(GPQ\0Q>*O!FKWNO:=IV
MMPV&JZ9'=7GAG7M2\,:["++6K&VN8S;Z]H^I6Y+PJLAM3)$SQ,CM>U/X@^#]
M'\<>%OAOJ6L+;>-?&NC^)=?\,:)]BU*9M4TGP>^D)XDN_M\%FUK9"V;7M)^2
MXGBDF^U_Z.DOER[`#LZ***`"BOAWXF?\%(?V,/@[XD^-OAKXD?&>U\,']FVP
M\)7?QX\3S^$/'E_\/_A7=^.=0\*:?X7\.>+OB'I/AB?1=.\971\=>#[C^QC?
M'4XK'Q#;W\UK':%YE^@?"'Q_^#?C_P"*_P`4?@=X+\?Z'XD^*OP5T;X?:_\`
M%/P?I;74][X,TKXK:;J>L_#RYU2[^SBU=M4T?2+ZZ@CAGEE6W2.69(DG@,@!
M[#2Y/J?S-)10`>_?UHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_`W_@I
M4WQ#US_@I]_P3%\)_"?]HGPG^RSXYM_@?^WUXFA^+/C;P%X1^)NAC1ETW]G_
M`$K4?#$7@_Q?XOT6"YU*Y::&=)X[PRP1Z9(WDR0^>4^4/V-_BQ\5?@C\-/CE
MX"T7XM:3\8_%&G?\%N_@%X/^)O[:?PZL-*TOPC^U\_[1_B_X2ZI\5H?^$8L4
MNM+\+:QH/A_7[+P;KEAH-Q<:9;OX8C^QW:71NPG]#7QX_9'_`&7/VHI/"4O[
M2'[/7P<^.LO@.ZOKWP6_Q6^'WAGQRWABXU-($U)]%/B'3I_L*7"6MJ)T3"3?
M9H_,5MBX[CPS\$O@UX+\#^$_AGX.^$_PX\*?#GP%J&E:OX(\!^&_!7AW1/"'
MA#5]"O\`^UM&U;PUX=TW3HK31=4M=5_TJ"XMXHYHKDF='$I+T`?S??&CXW_%
M/QE\%_\`@I]^USK_`/P4:^*'[,WQV_8T^-WQ]\)_!?\`9X\/^)_A[HOPL^'F
MD_`B7/P8\&?%#X-:EHUW<_&F[^*5O%HUY)?7LSS7L/Q"M+;PU]D-HOF]QX`T
M#5;C_@K1XV_:6\5>-/C[I?[04_\`P2)^`?QVT_\`9I/Q7N;7P+J_C#6/$_Q4
M/BWX)Z=X0NK<-?\`@^S\7:'I#0Z5$[);:WKE]J+2++=A!^X'C_\`8O\`V1/B
MK\6/#_QW^)G[,GP)\??&?PJVG/H'Q1\7_"[P=K_CG39-&=9-%EB\1ZEI$ES)
M-8R*K63R2.UFRAK8Q,`:[?QA^SW\"OB#\3?AW\:?''P@^'7BSXO?"1=0C^&/
MQ,U[PEHVI>.?`<6JAO[1@\+^)KFT:[TBWE9W9HXI53?(SA0[,Q`/Y1/^"<?[
M47_!2_XW?$']@?\`:+U_XEZW)I7[2OCOQ(G[1?ACXQ?MH?LL:K\&_B)X1O\`
M0/$>I:IX#_9J_91\*Z/'XL^%'Q2\&W-A9RII@F_M6*V\,W]OXF^TW-S+);_?
M/_!/GQ/XF_:3\"^%_P!LOX]_\%$OC!X<^.OC3XW?';PGX@_8^MOB;\-/"?P1
M\(7/A3Q?\1/!&B_LI2?`G7/"QO[GQ3IWAWP_IE]/?^;%XLOKF-KY;H6DVUOV
M)\$_L6?LA_#7XP:_^T#\/OV9/@5X*^.'BF;5+KQ!\5_#'PP\(:-X\U.[UUD;
M7;V?Q)8Z4ERM]?,BF]G1UEN^?M#R9.9Q^QM^R4OQND_:47]FCX%C]H&8RO-\
M9A\+_!W_``LB6YGM_L<^H2>+?[(^V/JSV7[A[PRFZ:`F$S&(E*`/Y@O^"?WA
M+XU?LG?LC_\`!$/]H?PI^U[^T1XST?\`:6_:0^''[/?Q%^`/C/QSHFI_L[VG
MPA^./A_XU:CH_AWP1\/K7PX/[!UOP[JGAG0+FRU07[ZC,]M<V]S*;69;6#U?
MP5+^USX)^&WPJ_;IU7]MS]J/QGXNUO\`X+!ZO^SS)\)/%?C;2+OX`2_LJ^+?
MVX/%7[,/_"O+_P"&\.A00WNHPZ';V>IV6NF9]4M+V&WMK:2*QB$*_P!/*?";
MX61Z%X'\+Q?#?P)%X:^&6KZ3K_PX\/0^$]"BT3P#KN@V]Y::)K7@W2H[$0>&
MM5L[74=0CMKBS2&6!+Z98G42.#H?\*\\`?V3::`?`_A$Z#8>(U\8V&B'PYI!
MTBQ\7)KDOB=/%%IIIM/)MO$(\2S3:B+U$%P+^5KP2?:&,A`/YE_CU\:/&?BS
MX=_\%2?VLO$'_!2KXQ?LX_'C]A+XW_M!>!/@G\`/#/C#P?X)^#?A73?A!ID&
MI_`'PW\1?@5XET2:;X[W'Q/MGTJY_M&_EF.ICQREEX;^RR::E8OQ@_:\_:"^
M&FN_\%-/VD=(@M_A'\:+;]@/_@C[>>)M7_X1]/$X^`,7Q>\5?&.+XO\`Q$O_
M``MJ`G75$\$6/COQGJ9@N8GA">%4DNXI8(IM_P#1=XV_9)_99^)7Q/T/XU_$
M/]G'X'>.?C!X;.FG0?B=XM^%W@OQ#XZTM]&9FT66T\3ZKHTMW'-8NS-9/YI:
MT9BUN8R2:];D\#>"9=2\3ZS+X/\`"TNK^-]'L_#WC35)=`TJ34/%^@:=!?VV
MG:)XHO'M3)K^D6]MJNJ1P6UVTL,4>I3I&BK-(&`/YU/%7QH^,'[&O[2^G?#C
M]E7]KOXM_P#!0+2/B;_P3U_:[_::\1?#7XQ^/O#7QWU7PAX\^"?A'P_K_P``
MOBAX1\5>#=#M)_#G@_QQXLURY\/C0(6.FZBXBGT:"%K>6OGOP5\7/%7A*^_X
M(Y_&CP)_P5N^,WQ^^)/[<7[2'P6T[]I/X%:]\3OAEXC\!^/M!\9_#+Q9XK^(
MB^!OA)I?AF.^^!WAGPMXTL+#1;K2]/DMH(UU"*RUA)-4ABFK^D?X5_LE?L]?
MLZ:+XZM/V6_@G\%_V==>\=6U]+J.O_#7X5^$_#_VG7)(;DZ1J>NV.A6EDWB&
MQLK^X$T5A+/'`%#PQ&!9"P_*#X=?\$L?C5XH_:8^`_QJ_:+\&?\`!.7P0?@)
M\7H?CQK?Q3_9!^`>O_#[X\_M.?$[P_X4\5>%?"%Y\4-4UZ%8OA]X9%WXNO==
MUC3;'4M?_M'5=.M8?M,5HC%@#XD^.7[>'[76J_"[X,^$_!?C/QS9>$?CI_P5
MU_;U_9J^(OQ+T?XK_#[X+>/-!^&GP:\?_%J;X1?!3P;\;/B3IUUHWPLU#6;W
MPM;:987AB6^GL_##:+IES!J6I02UI6GC#_@I9JO[%_Q3\#Z5^T[\.=-UO1?^
M"A/A+P/\.[+4_P!OKX.ZO^T_XO\`@4/#:^,/B5^QR_[7VG>#)M!\,?M)_P!J
M;9="O+NQDUF+0Y9K&^G6:&.Z?^E?7_V>/@)XK^'GB7X2>*/@M\+?$?PL\9ZW
MK7B7Q;\.M=\">&M7\$^)/$?B/7)_$VO>(-:\,W^FR6>H:W=^([FXU">[DB:>
M2]F:Z:0SDO7#WG[%G[(-_P#!`_LU7?[,'P%F_9]-ZNI_\*8/PK\&+\-UU=;C
M[4NMIX2CT<6<>N"ZS)]M6(77F,7\[<22`?./_!+#XUZ!^T9^Q9H&J:3XO_:'
M\1:CX2\:_%WX,^.-2_:.\5^"?%_QN\/>/?A]XYUSPWXL\-:K\3_AA:Q:)\0X
M]'O@;+2_$FF&5-1M+"WNI9Y+OSR/P$^`<'CG]EK]G#XV:)X2_;!^/OP]T#]I
M+_@NM\8?V1_C#^T=\0O']EXNO_@A\,K7XD?$.&^^('A74?$6CG2?`'Q8\8ZW
MH_AGPWJ/BR^ADA34_&-KJ30QW$$&/Z[OAU\-_A[\(?!7A[X;_"KP/X3^&_P_
M\)V*Z9X8\%>!M`TOPMX7T&P1VD^RZ3H>C6T-O91F:221_+C!>25Y'+.S,</4
M_@A\&=:\%>./AOK'PG^'&J_#WXF:EK^M?$7P/J/@OP]>^$O'6L^*KI;_`,2Z
MOXM\/7.GM:^(-4O[](Y[NXNHI9;B>-997:0!J`/YHOVB_C[^TK^S7IO_``53
M_9X_9Z_;1^+'QN\#?`_]@3X=?M&?#OX]^/?$?@OXI?%']F/]H+7OB)KWA>]^
M$6J_$[2]#B'B>/6O!?AVV\16MAKD%UJFGP7$Y28VEU:"OZ,_V:/@YKGP,^$^
M@^!_$_QH^+GQ_P#$YD?7?$OQ.^-/B*R\0^+M<U_5[>TEU86:Z7I-C9^'O#*W
ML<S:?I5E:Q6MA%.88@1EC5^&O[)/[+OP<^&.M_!7X4_L\_!OX>_"/Q//=77B
M?X<>$OAWX7T3P=XFNKWRA=77B30K+34@UZZ=8(%:2[29REO&F[8B@?0HXQCC
M&`,=@.@'I0!_!?\`LN_%CXF_\$N/A]XM_:!^`_@/QIXZF_X*D?%/]M_]FC0/
M#VF*VLZ5X:_X*1?#K]L7XV>#?V7?$>K:2U\8/#WA;6_ASJ^KV6K?8=\:GX41
MR^4Q+,_M?@:?XF_\$=_V4?\`@KO\/_V.YM6U;QS\.OVQ/V%OA9<?$?Q5?:%K
M>JZ=XZ^/GP6_9YTGXX_&Z2X^(%X-(L;F]\8>--;O=,D\02QZ'IUWKMK)J`.G
MVDD3?V067P@^%&FZ3X>T#3_AIX#LM#\(^+[OX@^%-(MO">APZ=X:\>7]_K&J
MWOC70+-+()I'BN;4_$.OW$NH0+'=O/K=W*TI>XE9\/4OV>_@5K5C\8-+UGX0
M?#G6=+_:"N(;KXXZ7J_A'1=3TWXM7-MX>T[PG;S_`!`L+ZTDA\421^&M'TJR
M0W:2;;?3H8UPL:8`/YP=<_:G_P""F7[$OPH_;U\5^*U\<:Y\+/AI^S'\*_B)
M\)O%'[77QK_94^.OQN^$/QA\>?%:T^'7B/Q5XCTK]E]+=M8^`MMX)UZX\7HV
MNV<:Q2?#K4+&SOGL)F2W]$^)OPF^)7P=_P""B/\`P1L-[_P49^('[6FA_%/X
MQ?'+Q?J/PW^-#?!N^O=9O+?]DKXLF3XW_!F\^%G@G1Y/#OP_CLM3DL'T</>Z
M.C^)K&6UF,XE:;]L/@=^PU^Q[^S7X5\>>"?@9^S?\)/AUX6^*436WQ*TC1O"
M.G3P^/M.-G<Z;%HWB^;54N)?$.@0Z;>WEM;:?=22V5K;W<L%O;Q12,AXGX,_
M\$T_V!/V>/'6A_$[X)_LD?`_X;_$3PM)J#>%/&GASP780>)/"<.JZ7JFBZAI
M_A75I_,E\-:/+I>M:K"UC8M!9A+^3$`+9H`_'GX4?M7?M8_M)?#;_@E9^SUX
MT_:;\8?LZ^+?VP="_;,\6?&;]H3PSX=^&=K\5/&%U^SUXXU#P]X+^!_PTU3Q
M!X+O?#/A'XA:AIFL)JNH2V^DSWBZ9\.+V/306DGNE^Q]1^(7QQ^`_P"T!^RE
M^SAI_P"UCXV^/?A75_V2_P#@H%XW\5?$?QGH/POU3Q?XU\7_``GUOX+?\*PU
M#Q1K'@3PI8:<FM>&;7Q?K5B9(;6V34GR=4@GNVWK^@?Q#_8L_9,^+/P@TCX`
M_$C]GCX3^,?@QX>UR3Q-X<^'&L^#]+G\,^&O$<NJ:EK,NO>&K-(5/A[5WU/6
M=7E:XLW@E8ZK<J7*32*VW\./V3_V9O@_H/@KPO\`"[X#_"SP#H'PX\,>,O!G
M@32_"W@W1M(MO"WA;XBWNG:EX_T31Q:VRFULM;U'2=,N-5`);4)[&*6Z:61`
MP`/PH_85\8?MS>$-%_X)!?'OXP?MK_%;]I!_V_?!OB#3?C[\,/B#X:^#VF?#
M?29]:_9G\<_M!?#/4OA3!X#\!:3>^$O$FFW_`(-@TV]NIKV^CUF#4[B6\@A>
M.W2'P#]C?]L[_@JY^U'=_LX_M8:!H_QC?P5\4_VIKWP3\3?`GB_Q[^PCX8_8
M[T#X(I\5?$O@;Q=X"\#>'5OH_BTWQC\.:)H22V%S>W,FKZMJ>DW:7&C"SN8T
M7^H_2_@[\*=$TGX6:#I'P\\(Z;HOP/6U3X/:59:'96]A\-%L?">H^`[,>"[:
M.(+H/E>#-7U33$\@)MLM0E@&(W8'Y[T+_@G=^P[X8^/MU^U%X?\`V7OA%I/Q
MZN]?O_%TOQ$LO#,,6H1^,M5M9+'5/&]GI0D_L[3_`!S<VDTR7&M06<>J3K,_
MFW;;FR`?#7[7W_!%[P=^VC\:_BQ\0/B3\=]=\(?"_P",/ASPCX5^(/P;^$GP
M^TSP#%\6-&\+^,?AAXKBM?C_`.+[+Q/(/C%/;0_#N^L="U"72]-UG0+;Q=<)
M;ZI<16MK"GM'_!.__@E5\*?^"=7B3XJ>,O`OQ/\`BC\5/&'QH\(?#OPO\1_%
M?Q5U-/$'B/Q-<_"W7OB)+X+UR^UNYDEN3<67@#QEX:\+06RRK:1:9\.-.D2$
M7,US(_ZE44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!117\UG_``<&>._^"C/PM?\`9=U[_@F7\;_B
MCH?QY\1WOQ:U/6_@!H%I\-]>\&?$CX8?`WP%>_%3QIXAB\-^+O"5UJ&I>,+8
MII&GI:6%\@U.'7X[)+8WAMG8`_I3HK^8+P+_`,%/W_X*J_\`!/\`_9+^+/[/
M7QM^)'[-'[1^M?ME_LS?L]?'_P`"_"'6O#\.N^#_`!1XO\806GQ9T36=/\5^
M']0-SX$U+X6Z3XXUKPY=21HT+01&9YKK3+ZV7^G.RM3965I9&YNKTVEK;VOV
MR^D6:]N_L\21?:;R94437<FS?(X50SNS;1G``+5+@^AI*_D'_P""TG[3GQ]^
M%G_!8_\`X)R?LU_#O]L_]I#X#_!/]I#P[%K'[1OA;X6ZJMW;:7X*T'Q7>6@O
M/`ND:)X%U75-"\0ZAI?AGQ#%<WD45W(K3QW"FW@BE*@']?&".HQ17YD?\$WI
M_`OB^T^/'Q/^$/[6?[67[2OPINOB/)\)-,TG]J*=[T>!/'7P=-]IOQ#O?AQ?
MZYX-T?7;G0M2U37;2VNQJD;(MYX2D^QHD1+/^F]`!2X/H?RKY/\`VX_AC\5O
MB]^RC\<?!GP)^*7Q`^#7QLE\`>(]8^$GCWX::Q!HOB/3_B-H&EW>K^#].GGN
MK2>*ZT"^UVTL;/4;9XR)[2\E56C?8Z_P?^+/^"G?[87C#_@@'X%_:B\*_MX?
MM*^!_P!NOX$_MA>-_@5\6M-B\6P:CJOQ7TW5HKOQEJ$.L^'1X7=M(M?#WP^;
M0+R"[_<6NG)H&JPW,DD^H14`?Z.&#SP>.OM]:2OP.^'_`,8]9_;V\.?\$E]&
M^`'[0G[07@>U\3_!/0OVN/VCO%7@WXA+#X@U3X,Z'X5L_"=M\/OBM>SZ7)'K
M'B3Q5\>V_LZ.Z"6]T+/X>>+WM?+='"?OC0`4N">@)_"DK^,?X[?MW7'A+_@N
M+\?/V7_^"LWQ5_:2_9R_97\5^'?"V@?\$^=;^&7Q2^(_P,^`BS7(TUY?B'XV
M\7_"[6-,N?$?B>_U*^FA36-3NKS2_#VHV,^G:C;VUL8)X@#^SBBO/_A1X/F^
M'WPS\!^!I_'WC'XIR>$_"NBZ`?B1\0M5L==\<^.$TVQAMH_$WBW6],L;6WUG
M7[N)$EN;J*WB6XED:78"YKT"@`HHHH`*7!/0$TE?R>_\'1/[27Q7_9RM/^"=
ML7P6_:B^+O[+WB3XS?M*R?#KQYXN^'WQ:\0_#[PY#\'HXM#7Q=K'BG3;*^CL
M9387_B+1KI=3N$\RS@M)XPYAED``/ZPL$=1BBOYF?^".?Q5_:Q^)'_!0']OZ
MS\$?M"?%?]JS_@DKX.DL_#'[/7QQ^-OBJ+XD:CJWQSTIO"*^-/#GPB^*=U:I
M?>/?`NFW5UXZL[RZ,MSIW_$NTMK>9[B2::?^F:@`I<'T/Y&H+FW6[MY[5Y)H
MDN89('EMII+>YC69#&TEO<0L'MYP&)21"&1@&4@@&OX0/^";7[86J_$CQ)_P
M5=^(O[6_[6/_``5`^(?P9^!7[3<_PC_9ET3X,?$_]HWQ!#H7A[4?B%XZT+1(
MCXR\`PI:2^(S#<>`(8Y_$M_#:06Y6ZN@PFDE(!_>+17"?"_P3+\-?AQX%^'T
MWC#QI\09O!7A/0O#$OCGXCZNGB#Q_P"+I-&TZWL7\1>--<CMX5U?Q/=M"9KV
MY$48FN)I'"+NQ7=T`+@GH"?PI*_D]_X."_C1^T5X4_;I_P""0O[._P"S7^TE
M\??@7JO[5_QCU#X=_%C3_A/\6/$_@W2-=^'<?CSX8:1'<R:)I,DD6G^(D@\4
M^*E358[?[0T:)&[.EK$(_P"K+2=-BT;2]-TB&YU"]ATJPL]-BO-6O[K5=5NX
M[&WCMDN=3U2^D>;4M0D6(//<3.\LTKM)(S.Q)`-"BBOG3]KZ\&F?LJ?M'ZRW
MBSQ?X$_X1_X(?$[Q,OC'P#X@G\*^,_#<GAGP?J^O1:KX;\16Q#Z3JD4NG(8Y
M5/&2IX)H`^C,'T/Y&DK^)/\`X(T?M%>.OVL/V(O@QXG_`&O/^"B7_!1BU_:@
M_::_:BU_X-_"#6/AAJ7B>U\-Z):Z%;M=Z##>7NJ?#*X\(:AI+V_A#QC<ZK<W
M]U=RR13-:1HMU`43^VM0555+,Q50"S8+-@`;F(`RQQSQU-`"T45^'/\`P7B_
M:R_:%^!/[&GQ2^'7[%DVHI^U;XJ^$/Q*^+/_``D&@WC66L_!C]G3X-6FGZO\
M:OC-;W\:M_9NMQP:AHNA:"&V2W&J^*Q-:,7TZ9HP#]QJ*_,'_@B[^T+?_M2_
M\$M?V*/C3KGBC6/&?BWQ#\%M%T/QYXG\1:I=:UXAUGX@>!+W4/`OC?4==U2_
MFDGOM4G\2^'-2FDEE8O)]H#G`8"OT^H`*7!QG!QZ]OSKS+XTZO\`$70/@[\5
M]=^#^@6/BOXLZ+\-O'&K?##POJ<ODZ;XC^(6G>&=3O/!NA7\OF)LL[OQ%#IT
M$AWI\DY&]/OC^2+_`((<?M;:1^WU/>?#+]J+]MC]MSX3?\%9?A1\:-3\>?%C
MX4^*OBAJ_P`/_"?C'P9X.\=#5KWX9>!_@!J.F+X2E^&R^%(5TGQ'H7]CQ>)-
M/E>ZU6&XB@^SW40!_931110`N">@)_"DK^-[XT_M/_%NX_X.-_B=^R/XB_;7
M_:Z\"_L<>"?V>8_C'\0?`7PLUWQ;J":%X^O_``-I>KVNAZ4W@+P!J.J>&_"*
M/XET*Z$40$9>W\EKPO<^3)_2)_P3VOO#?BC]F?PS\4?`GQM_:$^/'PU^-.KZ
MS\5OACXI_:::-OB=HO@/Q&UM:Z)X6+/HEA>'PQ$=*N;W3/[4A;4_LVNJ+J5F
M"JH!]NT444`%?FA\1/!7[2&N?\%2/V>_BC;_``(N/$'[,7PK_9O^,WP^'Q8C
M^)OP]TZ;PW\5/C/XG^&VLZCKG_"N;_5!K.K:-;>&/A=;Z3)+!$)C<>)1)%!-
M;0RRK^E]%`'\Q=[_`,$%[;X5_P#!<OX&_P#!1#]G>+2_#?[,GB;4?B)\4/VC
M_A%IVM'0M+\-?M`6/P_\7:1X&\:^'?",4J0:YHVL>)?&-Y?O#&CG1=5%_<PH
MEKJ"I!_3I110`5_*[^T3^QW_`,%%O$7_``7Y^%G_``4N\-_LAVWQ/_9Q_9X^
M#VL_!KP)H</Q_P#@MX2\:^*9]2\&?$C2&\<Z=IOB#Q'&NDV+>(/B+<.MK?M%
M=?9K)F=$D9(1_5%10!\M?LO>./VBO'>G?$;5/C_^R_X?_972'QL8_A]X2T_X
ML>$/BQXC\6Z%<:597NM^-_&6H>`[%-+T/5;KQ)<7\<=I%<7L[168N+FX+RA1
M]2T44``X(/I7\S_[(/\`P0`\$_"+]I#_`(*[_$CXJPZ-J_PY_;9U#XG?#_X`
M^&K.^-W8^"/A)\>/#KZ]\5]8FT*)%BT/Q-)XPUM-&M64?:4TWP(LBR"'4"E?
MTP44`?B#_P`$$_\`@EOXC_X):_L9?\*U^+6HZ1XC_:%\?^+]:\1?$[Q!H^IW
M6N:;IOA_2]4U2P^&_@#P[JEW(=OAC3M$N+W4A;0QPP1:MXWU>18V>:263]OJ
M**`(Y3*(I3`J-.(Y#"LA*QM*$/E+(RC*QE]NXCD`G'-?S,_\%2?V1?VY_P#@
MKQ^R+X._9(^(_P"PM\,_@=\6E^)_@WQ!J?[3GB?X]?#GQW\+/@W8:'JKKXO\
M8_"&S\,&;QIXGNM;\.6]Q8KHM]H^BJ8-:4:A>;[6*2OZ:J*`/-O@U\.8?@]\
M(/A5\)+;6]2\2VWPM^''@CX=6_B/665M7U^#P5X:TSPW%K.J%/E_M"ZCTU9I
ML<"29@"1S7I-%%`!1110`5_-'_P6!_X)M?MD_MU_M_?\$]OC'X%^$_P*^(G[
M+?[&'BZV\;>.?!7Q.^+;^'-7^+]QXB\7>$]8\8^'(_#,GPVU6TLM-BT/P?8V
MP^VSS1Z@UW)&\=M$"S?TN44`?SL?\$G/^"<?[:__``2U_:@_:A^#/AR\^%?C
M[_@EW\9/B+XD^+7P3LF^(6MVGQ7_`&?_`!!K"?:8O#UOX*O/"3VNLZ/-I\>G
MZ->B'5(Q(WAVQUB,B2:]MG_HGHHH`XWXBWWC73/`7C'4/AOX?T[Q7\0+3PWK
M$W@OPWJ^O)X6TK6O$RV,W]C:?J7B.33;P:)8R7YA$MS]DN3$FYA#(0$/\RW_
M``2%_8Q_X*K_`/!+3]E[X[_!Z_\`V6OV6_C=\5?B[\=?&7QNM/'47[6&H^#?
M"DFH>+O#7AW2(M+\8Z?)\"+V]N;6RU/099A]C&9H-3>-/(D0,_\`4W10!B>&
M6\1OX;\//XPBT>#Q<^AZ2WBF'P[)>3>'X?$C6%N=<BT*745%Q+HRZH;H6K3@
M3-`(S*`Y:MNBB@#^:+_@H7_P3_\`V]_VA?\`@L-^P_\`MU?##X4_!?Q/\`/V
M'M,6#3?#7B/X\W'@SX@?$W6=8GU[5]9U:UL_^%9ZA:>%X;34=5T:."&XN;@W
M?_"/RN\ELMRGE?MU^S]XS_:[\9>)?B+<_M'?`WX1_`_P391>&K?X5:9X'^,^
MJ_&7QMK]TPU:3QAJ?C:^/P_T'3?#VGI_Q(8].M;1;V9V^UR7$ZJ(4KZCHH`*
M^#?^"G/P[_:`^,G["'[3'P4_9A\*Z-XK^,GQJ^%OBGX2>&X?$/C#3O`^BZ%;
M?$'2;OPWK/BC4-:U*VF62&QTJ^NI!;1IYUP[*D;H<N/O*B@#^=[_`()C?!__
M`(*1?L&_L+?LI?L6M^PU\)-<\3?"O7[W3O&WQ;US]JWPG+X#TC2O%GQ6UWQ1
MXG\?Z)X9TKP7<:SJFMP^%?%6K>1IL0M2U["(?MIMY7D/]$)ZG'3M110`C$A6
M*J78*Q5`0I=@"0@9N%).!D\#.37X3VG[`OB;]K;4?VY?C;_P4'_9!\"ZU\8?
MB!9ZY\*OV8O"D'QETOQE#X>_9LTCP1+9^#O`.E^(;"SL[7P-XAU+Q]?>)-=U
M^><7-O<:EXD@8%K72[9%_=FB@#^?W_@W=_8X_;A_X)\?L@>(OV1OVP_`/@71
M=-\'?$;Q)XX^$OC/P/\`%+2_'<.I:%X^EMM1USPCJ6CV>E02:1<V'B*WU2]6
MY+O%<KXB\M4C:!BW]`5%%`'A'[1_B[X]>!/A=?>*OV;_`(0^'_CM\2M)\0>$
MI3\+-?\`'EC\-3XH\'2^(].@\=1>'O&&L0/8:;XP@\*RZG<:4FHF*QN+RTCM
M[F>&.0R+^"7BW_@F]\:?VQ_^"SG[*7_!2#6_V9K']BGX>?LL^%;R]\=Z[XE\
M;_#O7OCC^T]\09-.U*T\+:1>^'/@_KVKZ;I7AG1;759+.XU?5-6-_?V3S6*V
MLEK':>3_`$R44`%!Z''I110!_+A^S-^Q_P#\%*/@)_P6!_X*`_\`!1_Q;^RK
MX/\`B)X,_:@\'6OPZ^%?A/1_VEOA]IOB[PKX;\*W_@:U\//KMQK6E^1;VM[H
MW@.REF@MI9#:S72Q[9UCWC^B#]GG7OC7XE^&=CK'Q]^%'@_X(>/;C6O$D</P
MQ\$^.8OB/I?ACPE;:S=VW@^*^\86FC:?:ZIKT^@Q6=S>K9VD=I;S79MX3((C
M*_M]%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
)110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g246642002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g246642002.jpg
M_]C_X``02D9)1@`!`0$"6`)8``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86
M&#$C)1TH.C,]/#DS.#=`2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!8`CH#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#OZ***`"BB
MB@`HHHH`****`"BBB@`HJKJ5S/:V4DMM;^?*!PI8*!QU)]*K3ZNMOH,6HR*N
M^6-"D>[`9V`PN?J:`-.BLS4]0FLM-@F5K822.B,[L1&N>ISZ5'>:E<VFD)=-
M)9/(\JHL@8^4`S8R30!KT56T^6::V$DTEO(6/RM;DE2/QK,O-6O8KC4#$MGY
M%EC(E<JS_*&.#T'7%`&Y15-]4LX;>"6ZGCM_.0,JR,`>1G]*KW6KQ6FJ0Q3S
MPQVTENT@9C]X[@!@]^#0!J457:^M$M!=-<Q"W/23>-I_&D;4;);5;EKN%8&^
M[(7`4_C0!9HK.M]<TZYO7M(;J-I%0/\`>&"#GI],<U9M+ZUO58VMQ',$.&V-
MG%`%BBL>_P!1NXM1DMX);&*.*%9&-RQ!;)8<8/`X_6K$&K0?V7;7MZ5M!,H.
MV0]SV'K0!H45#'=V\J1/'-&ZR\1E6R&[\?D:KWEZ4EM5@D0[KD0RCKCY2<>Q
MZ4`7J*JKJ5D]X;1;J(W`X,8;G/I]?:I!=0&..03(4E;:C`\,?0?E0!-152#4
M[&XE>.&ZC=XP2P!Z`=331J^GM;M<+>1-"K!2X;(R>@'J:`+M%9NFZDM_?7JP
MRI)!#L"E>Q()(-3ZM=/8Z5=742JTD4990W0D4`6Z*Q_[9D_L6>Z,*QW=MA9H
M7/"MQ^ASD&EEU::&TU(M&AN+639$@X#[@/+_`#R!^%`&O163!JLTUKIQ$:+<
M7,FR5/[FT'?^1&/QK6H`**@OKRWT^TDNKJ01PQC+,:9INHVNJVBW5E+YD1.,
MXP0?0B@"U1163>ZR++5#:,@=FA5H8U^_(Y8C`]N.O:@#6HJ@MXUE9QR:M-"D
MTA^[&"0/]D=S@=Z<^K6$=O%.UTGES9$9'.XCJ`.N?:@"[15)M7L$M8[EKI!#
M(VU&YY;TQUSP>*<-4LC9?;!<+Y`.W<<CG.,8ZY]NM`%NBJ1U>P%L;C[2OEA]
MAX.[=Z;<9S[8I9=4LXH(IWF/ERC<A5&.1ZX`H`N456^WV@C>3[1'L2(3,V>`
MASAOIP:?'=02M&L<JL9(_,0`_>7CGZ<B@":BJVHW@L+*2X*[RN`J9QN8G`'Y
MD52SJ$$L+W>IV:%V&8#'M!]0I)R30!K454N-4LK6<0SW"H_!(P2%STR>@_&F
MW6K6-G+Y5Q<!'QN(`)VCU.!P/K0!=HJK)J5G'<QVS3KYTH!1!R6!Z'CM[U#_
M`&YIOFB/[6F2_E@X.UFSC`.,$Y]*`-"BJ7V^*&&22XG5E64QCRT8D?[.!DDU
M8MKF&[@6:W</&W0C_/%`$M%9%Y=WEIJ$(-U;N)YE1+4)\Y0]6SGJ.3TQQ44N
MH7_DW6H1M']EMY&40%/FD53AFW9X/!QQVH`W**S;J[O(]6LXDCB%G,Q5F))=
MCM+<#L.*CUC4KBUFABLXT<^8AG9NB(S!?S)/'T-`&M161K6ISV;PQ6<:R/O0
MS%NB1E@OYDGCZ&M>@`HHHH`****`"BBB@`HHHH`*B9R&(\U!STQ4M0LV&/[Q
M!STQ0!-1110`4444`%%5Y+^SBV^;=P)N&1ND`S1)?V<2HTEW`@<94M(!N'J/
M6@"Q14+WEM'`)Y+B)86Z2%P%/XU(LB-C:ZG<-PP>H]:`'444Q)8WC$B2*T9&
M=P.1CZT`)<(9;>6,=70K^8K&GTV46FD>9:K=BS0+);Y')V`;AG@XY_.MA[F"
M.#SY)HUAQGS"P"_G3H9HIXQ)#(DB-T9#D'\:`,>S@NK*RD(T]722X+K:AUS$
MA';MG(SC/>EM(+FSL[B0:<K":X,@M%=?W:X`X[9R,X]ZU)+NVBG6"2XB25_N
MHS@,?PHEO+:&98I;B*.1_NHS@$_04`4]'M9(#=S/`+9;B7>L`(.P;0,G'&21
MGBL^_P##_P!JNKZ\\B)KH2QRVS/@[BJCY3[$@C]:W)[RUMW"3W,,3$9`=PI(
M_&B:\M;<@3W,,189`=PN1^-`&;)'<P:E)?"P:X\^!$**Z[HB,Y7DXP<]1Z53
MM]/O;"XT^?[$MP(8)$=4<9B+-N`7.,X''TKHP0RA@00>014,-Y:W#E(+F&5Q
MU5)`2/RH`P)=)O6CAN4B>)A=O.;>%UW(K+MX)^7/?\35BWTEF%JTEN^!>-<2
MK.ZN?N$`\<=<<"MN&:.>)987#QN,JPZ&GT`9$]I(-5NV-F9X+JV$9(8``C=E
M3WYR.:-#AO(&F2:.6.V"HL2SLK2`C.1E>J],9YK7HH`PM1LI'U>6<Z/%J$<D
M"(I=T&T@MD?-]1TIEOI][8#3YVB%Y);Q/&\:ORFX@@J6ZX`V_2N@HH`P8K&]
MA6.[%LID^V-<-;*X^560K@'IGN?J:6VL+UI/.FA2-FU#[1L#AMJ;-O7UK=HH
M`YNQT>Y@FA@GBGDBBN#,)?M`"?>+`[<9SST_6K5OI=Q'JKL2GV*)GFMU[B1^
MN1Z#YL?[U;#ND:[G8*N0,DXZ\"J_]IV'G>3]MM_-W;=GF#.?3'K0!APZ9J<M
MU!+<AR\<4J2.\X979EP-JCH,U=_LZ>VLM*,,*226*!6AW;0<IM)!Z9!_K5UM
M5T];G[.U[;B8MM\OS!NSTQCUJ1[^TCNUM7N8EN&Z1EAN/X4`9MO]KLY[Z]FL
MU5KJ2)8X8WR?[I+$#'O^%7M7MI+S2KJVAQYDL95=QP,U:21)-VQ@VTE3@]#Z
M4DTT4"!YI%C4D+EC@9/04`8^NZ1<7:>;8LB3.%BG5_NR1YS^8['W-/O=+GGU
MZVN8V46N`TZ]V9,[/U;]!6A<W]I:2)'<W,43O]T.P!-2R2QQ*&D=44D`%CC)
M/04`9=GI<\.NW%U(RFUP6@4=59\;\_BH_,UKT57CO[2:Y>VCN8GF3[R!@2*`
M$U&PM]3LI+2[3?#(.0#@^H(J/2=*M='LA:V:LL8)8ECDDGN:ECO[26Z:VCN8
MFG7K&&&1ZTV+4;*:Z:VCNHGF7.4##/'6@"U63>Z,M]J;W$ORCR%2.13AXW#$
M[@>W45I&>(3B`RIYQ7<(]PW8]<>E)<W,-I`T]S*L42]68X`H`Q+O3]2N#9W,
MP$EQ:[T80S&+S5;&&!['CD58L]*:&2QD\I8_+>6213*9"&<8SN/4U>L]2L[\
ML+2YCF*?>"GI5J@#(BTN9;M)&\LHM[)<8]%*$#\<FH;[1[B9)FC(+?;1<HJR
M%"P"!2-PZ'K6[10!@#2Y!9NYL&:=YA)@WC&08&`P?L?;TH>RU9[>U2=VG`C9
M942X\L[B?E+,!\P`XX[\UOT4`<VOA^X%GID!>/;'&(;Q<Y#QY#8'XC'T)J>S
MLI]'^T2A!<#>L-K&G\$1;(!/L6/X`5NT4`5M1LQ?64EOOV,V"K@9VL#D'\P*
MRK^UU'4[=;6YL+4,&4_:1+D+@@DJ,9&<=/UK>HH`YZ]T>X:_O&6)KB"\*EA]
MJ:(+\H4A@.HP/Z59-I>65Q=_9+>*>.ZVD%Y-OED*%P>#E<`'\ZV*@>]MT95,
MRY,ODX!S\^,X^M`%'3M*-E,,L'5;2.W#_P`65+9^@Y%94IGCT^PT^)K.6)+F
M)4D23+2!7!X7'!`'//8UU55K>&Q,\DMO%!YJL5=T4;@W<$T`9TVGWRQL(7RC
M73RO&DIC+H1P-W;GFK.A6,NGV3Q3;=SS/)A7+8#'.,GDFK=W=16=NT\Y(0$#
M@$DDG```ZG-2(V]%;!&X9PPP1]:`,C4+6_OI!"8+=`LJLEV'^9%!!X&,[N,=
M<4V;3K[R;G3XO+^RW,C-YQ?YHU8Y9=N.3R<<]ZU;BZ@M0IGD";CA1U+?0=32
MV]S#<J3!('VG##N#[CM0!#=6SS7-E(A`6"0LP/IL8<?F*H:GH+77G/;WUS"\
MTJ2.H<;?E*].,]!Q[UM44`8FH^'S<B9H+^ZBDF>-G^<8.W'/3K@?G6TB[45=
MQ;`QD]32U!->6\$A260(5C,IST"@X)S^-`$]%5S>0B[CMAN:1UW_`"J2`OJ3
MVJQ0`4444`%%%%`!1110`5"SX8_O$'/3%35"SX8_O%'/3%`$U%%%`!575)7@
MTNZECX=(F*GT.*M4UT62-D<`JP((/<4`9.I0PV^DPVL$4332!;>W+*#@D=?P
M&3^%+J4,%AHR6\$$;R!5M[<,H;YCP/\`$_2KT%E'&EMYI\Z6V4JDC#D9&/SQ
M4LD$4DL<CH&>(DH3_"2,?RH`R(+*"VU6QLBH:*WLV$08<%LJ"?KC^9JO9`1/
M;/$!M34)H(\=/+.[('L"/TK;O+*WO547"%MARK*Q5E^A'-,73X4EMC&-D5LK
M".)1P">,_EG\S0!6UVX$<,-N_F+%</MED1&;:@&2/E&03TS[U2\/Q6>H^%H[
M8H7@0LK(0RCAB0.V1TKH:9##'!&(XD"H,X`]SDT`<_:6TDWA_1IX4CE%JBR&
M*5MH8;".O8C.14VB3.EK<:A+;/%'>3;XX(E+[5P!NX]<9_$5KFU@-H;7RQY!
M79L[;?2I54*H50`H&`!VH`Q?$<.[39Y88(&&`URYXD"+SE?]H#IFC7HA<Z1/
M+:06\GF1`S._#B/&<CCKCIG%7;G2+&ZG,TT&YFQO`8@/CIN`.#^-%UI%C>2F
M2>#<S`*V&*AP.@8`X/XT`9]Y`[G^U[3[++&+1?W=Q'DE1EOO?PY!]*=>6TUQ
M*FK6HM6_T0#R;E,\?>ZYXJ_<Z18W4PEF@!;:%(#$!@.@(!P1]:+O2;*\D$D\
M.YMNP[6*[E]"`>1[&@"2"<76F1W"KL66$.%],C.*P-"TVXN++2)G@M+>*W59
M`\63(_RD8/`QG.3UKIPJJH4`!0,`#H!388HX(4BB4)&@"JH["@#G-%N+^TT_
M2FFDBD@N'\GRPF&0'<5.<\].>.]3_P!IWXL?[5+P_9O-V_9MGS;-^W[V?O=\
M8]JV%LK9(H8UB4)`=T8_NGGI^9J#^Q['[5]H\CY]^_;N.S=_>VYQGWQ0!G-J
M.I!+F[W6X@M[HP^4$.77<%R6SP>?3M4=SK&HM?7B6=O(ZVKA!&L!82'`)R^1
MCKZ5N&SMS"\1A7RY'WLOJV<Y_.H;C2;*YN//E@S(<;B&(#8Z;@#@_C0!<!R`
M2,9[4ISCCK110!S'ABY\1S:I>+K$12V7.S*!0&SP%]1BNGHHH`H:BHDO-/C?
M_5F8L1ZE5)`_/G\*KW<<=]K=O;!%*6N+F4X'WN0@_F?P%:%W;"Y2,;RCQR"1
M&'8C_$9'XT^.&**21T15>4[G8#ECC'/X4`9MY&E[K5M:A%*6_P#I,QQ_%T0?
MGD_@*H3K%_8.LR.!YOVB4[NX<-\G_LN*Z)(8XY))$0*\A!=AU8@8&?PJ!]-L
MY+L73VZ&8$'=ZD="1T)'K0!#9Y35[Q!T:.*1A_MG<#^BBL3Q3<JSRK<PW'EV
MQC:$K$S*SE@2V1QP.!]37206RPRSR[BSS/N)/8`8`'L*DEB29"DJ!T."01D<
M'-`&3J$T4[&VLH$DOKR$!BZX\N+GYGSSCDX'<U6G@NY-1BM[62'RM+A1@MP"
M?,<@@$XZ8`Z^I-:EUHVG7DYGN+2-Y2`"YR"0/I3I]*L;D1B:V1_+78O7[OH?
M4>QH`BMM3-Y:0216\P:XA\Q6"Y53CH366BHFA:&;<#S_`#8]A'7<0=__`+-F
MND5510J@*JC``&`!5:'3;*"[:ZBMT69LY8>_7'IGVH`Q8EB&AZ&8O];Y\14]
MRQSOS^&[-6-1.V^TR93`U@+C"^5]_P`Q@0#GH1R<XYK2BTVRANVNH[9%G;.7
M`]>N/3--CTJPBN?M,=K&LH)8,!T)ZD#H#0!2EMH(?%5K-'&JRS02F1^[8*8I
M_B7?_9/[O;O\^';OZ9\Q<9]JTS%&TJRE%,B`A6QR`>O\A2R1I*NV1%=<@X89
MY!R#0!F33WMI8RO?20([,J1&UC).XG`&&/)R:HQZI?16FH^<Y$MFZ%/.5=T@
M(!V';QD]!CGD5OSPQ7$313QK)&W56&0:BBTZRAQY5K$N&#C"C[PX!^OO0!!H
MEW-?6;7%P0KM(P,(&##CC8??U^M:%,2*.-W=$56D.7('WCTYI]`'+^)!XD_M
MFR_LC/V7C?C&,YYW9[8Q74444`-D8I&[A2Q4$X'>N>TC4-5NGM+B2.1H;@%G
M5EC5$&"1L(.X^G/Z5T=58=-LH+DW$-M$DIS\P7GGK],T`4[V]NI8K5;59+-Y
MKD1,9XP3MVDD@9/I5*6YU2U@N[B2^$BVEPL83RE'F*=N=Q]<-VQTKH7C1RI=
M0Q0[ER.A]1^=-:")E=6C0JYRP(X8^I_(4`8>J:G<6]Q+-;22M#!,D4BE$$8)
M(R,GYB?F'2DN+EYKE%?;^ZU58UP,<;,\_G6Q)IUE+.9Y+6)Y3C+%02<=#]:E
M^SPYSY29W^9G;_%C&?K0`D`8*^^82G><$`#:,_=X]*QI+R\DF:""9(2U^8-X
M0$A!'N_//>MN.*.(,(T5`S%CM&,D]32"WA#;A$F[?OSM_BQC/UQ0!SM\;N>%
MK=[YPUK?Q)YHC7+@E2,\8R,]O2K<LUY//?E+];5;,@*I13N^4-N?/8YQQCI6
MN8(6SF)#N8.>.K#H?KP*BN-.L[J59;BUBE=>C,H)H`Y^2X>YO;>:ZBG1+F.-
MF$08L$VD[1CG&_KCVS4=E.]I%>WL<4RS012%TN"=V"WR`YY(4`\^YKJ)[>&Y
M0)/$LBCD;AT^E$-K!!&8XH41&^\`.OU]:`,N[:^L]->2/41/,YC"L\:X4LX!
M(`[<TE[?SZ0ZK<3&X66$B(LH!:8'A>/7(Q]*T(--LK96$%K"@<@L`HYP<C\J
M;=6DEU>V[2>7]G@;S0,98O@@>P`SF@"BKW\]S-;OJ`MVM8D+,L:_O&(R6.?X
M<\<>AYJK]NEFC6^`5)SI<D@XR,@CG![5MW5A:7C*UU;13,G0NH.*F,,3?>C0
M_+LY4?=]/I0!STDUQ;:C?7ZS/*R:<LJP8&"?F/UQD?K5C2+G47N8C<%VMY82
M[&5HP0>,%0I^[R>OM6T(T#;@BAMNW..<>GTJ"#3[.V9V@M88V<88J@&1Z?2@
M"I=S37&HQ6D-W]FB:`R^8@4M(<XP"<C`ZGZBH6DN;F^FMO[2-NMM"C!U5<RD
M@Y<Y&-O'05I36-I/"D4MM$\:<(I087Z>E)-I]E.L:S6D+K&,(&0':/0>U`&1
M:W=]JCVJ"Z-JLEJ97,:`EFW8!&0<`]:=I]Q?C^S)[F[\[[7E9(]@"CY2P*]^
MWZUN"-%8,$4,%V@@=!Z?2D$48"`1J`GW0!]WZ>E`#Z***`"H6?#']XHYZ8J:
MH6?#']XHYZ;:`)J***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`*IZQ<26FD7=S"0)(HF=21D`@5<JIJUL]YI5W;1XWRQ
M,BY/&2*`(HM9L9;>25+A7$2!WV@]/4>H^E5_^$ET_P"RV5QO;9=L%4;3E3C/
M/';I4\EC*VH03+M6-+5X6^I*X_#@U42VU!=*T]#:H9[*1,IY@PZA2N0>W7/-
M`%V76]-AG:&2\C$B'##D[/KZ?C5L3Q&;R0X,FS?C_9SC-<_;&],VL1VME#*L
MUR5WM(!M.Q0=PQR/I6D]O>0:8+*VVMMMUB64MAMWW2<>PYZT`-.HRG3I[I`I
M+RF.U&/O<[5)^IR?I5HW]K%$&EN8Q^\$)8G`\SIM^M1_8B+FSC50+6U0E>>K
MXVK^0S5"\T%[S4YVD=?L4B%UCQRLY&W=^`'YT`:XN[<W'D"9/-SMVYYSC./R
M.:B_M.Q^SBX%U&8BQ0,#D$C.1^A_*LM](U`Z*H6:(:KYQG,O\.X\'\-IQ^%/
ML]!^R:FI0I_9Z1DI#CD2D;6/T*C\R:`-47EL9DA$R>8\?FJN>2GK]*7[7;_9
M/M9F06^W?YA/&/6N=_X1R]%L[+<1_;4?RH93_#;X*[?K@D_4"M6^L9I]/:T@
M2)4A\MH-S'#;"#AAC@<8H`D&LZ?]G:=KE4B5@I+J5Y/08([U,FH6CPRS"90D
M(W2%@1M&,\@^U598KR^%N9[:.#R;A)-IDWD@`Y[>IJIJEJ;C7;:&&1=EPN;M
M.I*(0R_F3CZ&@#0GUBPMIO*FN`K``M\I(7/3<<8'XU!-?2I?7R&>.*&&.%E9
MUR!N8@]/7`J*:ROXOM]O;0P2Q7K,WFN^#'N`!R,?,!CC\J;-HDQBN8HY%99(
M8(D+DY^0G)/X4`.@U2.36=0$MR\<-DH&PH53IEF)(Y]N:T+/4+:]++!(2R`$
MJR%6`/0X(!Q[U1U#2)KR+4X_,5!=&-HSD\%0.OXCM1IUA/!+/<FU2.X,?EQF
M2Z>4GO@D]!GTYH`NWFI6MDZI/(0Y&[:J%B!ZD`'`]Z9<:O8VTOERS?-M#-M0
ML$!Z%B!P/K4,L%];ZA)>6L,,QGB1'1Y"A5ES@@X.1S4<EKJ%O+>&UAMY1>$,
M2[E?+;:%.1CYAQ0!:N=8T^UD,<URH95#D*"V%/\`$<#@>]/M-4L[V4Q6\P=P
MN[[I&Y?4$CD>XJG:Z.ULEQ'N5TDM([=2W4[0P.?;D582R=+RRE!4);V[1$#U
M.W&/;Y30!?HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`J%GPQ_>J.>FVIJA9\,?WH'/3;0!-1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(J*N
M=J@;CDX'4^M+110`4444`%%%%`!1110`4Q88EE:58T61\;F"C+?4T^B@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`*A9\,?WH'/3;4U0L^&/[T#GIMH`FHHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"H6?
+#'][CGIMHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
